



**April 2015\***

Drug Information Update

## Table of Contents

---

NEW GENERICS TO MARKET .....	2
NEW DRUG ENTITIES.....	3
NEW INDICATIONS (EXISTING DRUGS) .....	4
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS .....	5
STUDIES and RECENT TOPICS.....	11
RECALLS* .....	22
CURRENT DRUG SHORTAGES‡.....	44
NEW DRUGS COMING TO MARKET.....	92

## NEW GENERICS TO MARKET

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME	APPROVAL DATE
METAXALONE	400 MG TABLET	COREPHARMA LLC	SKELAXIN	03/27/2015
ADAPALENE	0.1 % LOTION	OWEN LABORATORI	DIFFERIN	03/31/2015
NORETH-ETHINYL ESTRADIOL/IRON	0.8-25(24) TAB CHEW	MYLAN	GENERESS FE	04/02/2015
NORETH-ETHINYL ESTRADIOL/IRON	0.8-25(24) TAB CHEW	ACTAVIS PHARMA,	LAYOLIS FE	04/02/2015
BISAC/NACL/NAHCO3/KCL/PEG 3350	5 MG-210 G KIT	NOVOTEC PHARMA	PEG-PREP	04/09/2015
METOCLOPRAMIDE HCL ODT	5 MG TAB RAPDIS	GAVIS PHARMACEU	METOCLOPRAMI DE HCL	04/09/2015
BISAC/NACL/NAHCO3/KCL/PEG 3350	5 MG-210 G KIT	GAVIS PHARMACEU	GAVILYTE-H AND BISACODYL	04/15/2015
POLYDIMETHYLSILOXANES/SILICON	GEL	EXELTIS USA DER	RECEDO	03/26/2015

## NEW DRUG ENTITIES

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
PRENATAL VITAMIN PREPARATIONS	PREFERA-OB PLUS DHA	PNV NO.88/IRON PS,HEME/FA/DHA	28-6-1 MG	New Combination
BILE SALTS	CHOLBAM	CHOLIC ACID	50 MG	New Entity
BILE SALTS	CHOLBAM	CHOLIC ACID	250 MG	New Entity
SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	PRISTIQ ER	DESVENLAFAXINE SUCCINATE	25 MG	New Strength
PARATHYROID HORMONES	NATPARA	PARATHYROID HORMONE	25MCG/DOSE	New Entity
PARATHYROID HORMONES	NATPARA	PARATHYROID HORMONE	50MCG/DOSE	New Entity
PARATHYROID HORMONES	NATPARA	PARATHYROID HORMONE	75MCG/DOSE	New Entity
PARATHYROID HORMONES	NATPARA	PARATHYROID HORMONE	100 MCG	New Entity
EYE MYDRIATIC AND NSAID COMBINATIONS	OMIDRIA	PHENYLEPHRINE/KETOROLAC	1 %-0.3 %	New Combination
CEPHALOSPORINS - 3RD GENERATION	AVYCAZ	CEFTAZIDIME/AVIBACTAM	2.5 G	New Combination
INTRA-UTERINE DEVICES (IUDS)	LILETTA	LEVONORGESTREL	18.6MCG/24	New Strength
ANTIHISTAMINES - 1ST GENERATION	HYDROXYZINE HCL	HYDROXYZINE HCL	50 MG/25ML	New Strength
NUTRITIONAL TX, PHENYLKETONURIA (PKU) FORMULATIONS	PHENYLADE GMP	NUT. TX FOR PKU WITH IRON #57	30 G-396	New Combination
NUTRITIONAL TX, PHENYLKETONURIA (PKU) FORMULATIONS	PHENYLADE GMP	NUT. TX FOR PKU WITH IRON #57	30 G-396	New Combination
METALLIC POISON,AGENTS TO TREAT	JADENU	DEFERASIROX	90 MG	New Entity
METALLIC POISON,AGENTS TO TREAT	JADENU	DEFERASIROX	180 MG	New Entity
METALLIC POISON,AGENTS TO TREAT	JADENU	DEFERASIROX	360 MG	New Entity
BETA-ADRENERGIC AGENTS	PROAIR RESPICLICK	ALBUTEROL SULFATE	90 MCG	New Entity
ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST	SAXENDA	LIRAGLUTIDE	3 MG/0.5ML	New Strength

## NEW INDICATIONS (EXISTING DRUGS)

---

DRUG	NEW INDICATION	DATE OF APPROVAL	LINKS
BRILINTA (TICAGRELOR)	CRUSHING OPTION FOR ADMINISTRATION	MARCH 30, 2015	Brilinta® [package insert]. AstraZeneca April 2015.
MOVANTIK (NALOXEGOL)	OPIOID-INDUCED CONSTIPATION IN ADULT PATIENTS WITH CHRONIC NON-CANCER PAIN	SEPTEMBER 16, 2014	Movantik® [package insert]. AstraZeneca. April 2015.

### Feraheme (ferumoxytol): Drug Safety Communication – Warnings Strengthened and Prescribing Instructions Changed

[Posted 03/31/2015]

**ISSUE:** FDA is strengthening an existing warning that serious, potentially fatal allergic reactions can occur with the anemia drug Feraheme (ferumoxytol). FDA changed the prescribing instructions and approved a Boxed Warning, FDA’s strongest type of warning, regarding these serious risks. Also added is a new Contraindication, a strong recommendation against use of Feraheme in patients who have had an allergic reaction to any intravenous (IV) iron replacement product. All IV iron products carry a risk of potentially life-threatening allergic reactions. At the time of Feraheme’s approval in 2009, this risk was described in the Warnings and Precautions section of the drug label. Since then, serious reactions, including deaths, have occurred despite the proper use of therapies to treat these reactions and emergency resuscitation measures (see Drug Safety Communication/Data Summary). FDA evaluated this risk further and has identified ways to reduce the risk of serious allergic reactions with Feraheme. FDA is continuing to monitor and evaluate the risk of serious allergic reactions with all IV iron products, and we will update the public as new information becomes available.

**BACKGROUND:** Feraheme is in a class of medicines called IV iron replacement products. It is used to treat iron-deficiency anemia—a condition in which there is a lower than normal number of oxygen-carrying red blood cells because of too little iron. Feraheme is specifically approved for use only in adults with iron deficiency anemia in patients with chronic kidney disease.

**RECOMMENDATIONS:** Based on FDA’s evaluation, the prescribing instructions and other label information were updated, adding a Boxed Warning that describes these serious risks and recommending that health care professionals:

- Only administer IV iron products to patients who require IV iron therapy.
- Do not administer Feraheme to patients with a history of allergic reaction to Feraheme or other IV iron products.
- Only administer diluted Feraheme as an IV infusion over a minimum of 15 minutes. Feraheme should not be given as an undiluted IV injection.
- Closely monitor patients for signs and symptoms of serious allergic reactions, including monitoring blood pressure and pulse during Feraheme administration and for at least 30 minutes following each infusion.
- Carefully consider the potential risks and benefits of Feraheme administration in elderly patients with multiple or serious medical conditions, as these patients may experience more severe reactions.

- Carefully consider the potential risks and benefits of Feraheme administration in patients with a history of multiple drug allergies. Patients with multiple drug allergies may also be at higher risk.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm440479.htm>

## Products from Prescription Center Pharmacy in Fayetteville, N.C.: Recall - Lack of Sterility Assurance

[Posted 04/02/2015]

**ISSUE:** FDA is joining the North Carolina Board of Pharmacy (NC BOP) to urge health care professionals, including veterinarians, and patients not to use products made and distributed by the Prescription Center pharmacy, located at 915 Hay St., Fayetteville, North Carolina. In an inspection conducted in March by the NC BOP, state inspectors observed significant deficiencies that raise concerns about the company's ability to assure the sterility, stability and potency of the sterile and non-sterile human and veterinary drug products that it produced. The Prescription Center has been closed by order of the NC BOP, and the NC BOP has ordered a recall of all lots of sterile and non-sterile products compounded or repackaged and distributed by the Prescription Center between Sept. 10, 2014, and March 10, 2015.

**BACKGROUND:** Drug products made by the Prescription Center have been distributed nationwide and to Canada. Although the FDA is not aware of any adverse events associated with these products, due to concerns about a lack of sterility assurance and other conditions at the facility, and out of an abundance of caution, the FDA and the NC BOP are advising against their use.

**RECOMMENDATION:** Health care professionals should check their medical supplies, quarantine any drug products from the Prescription Center and should not administer them to either human or animal patients.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm441001.htm>

## Intravenous (IV) Solutions (Select Lots) by Baxter: Recall - Potential Presence of Particulate Matter

[Posted 04/10/2015]

**ISSUE:** Baxter International Inc. is voluntarily recalling select lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter. Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number, and composition of the foreign material, and patient's underlying medical condition. In the absence of in-line filtration, these particles may cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization. In high-risk patients this may lead to serious adverse health consequences.

**BACKGROUND:** The lots being recalled were distributed to customers and distributors in the United States and Bermuda between January 14, 2015 and March 5, 2015. See the press release for a listing of affected products. While Baxter manufacturing personnel were performing routine maintenance, particulate matter was detected and identified as material from a solution transmission system pump. There have been no adverse events or product complaints associated with this issue reported to Baxter. Baxter began the customer notification process on March 24, 2015.

**RECOMMENDATION:** Customers have been directed not to use products from the recalled lots. Recalled products should be returned to Baxter for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001, Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m., Central Time. Unaffected lots of product are available for replacement.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm442091.htm>

## Flurbiprofen-Containing Topical Pain Medications: FDA Alert - Illnesses and Deaths in Pets Exposed to Prescription Topical Pain Medication

[Posted 04/17/2015]

**ISSUE:** FDA is alerting pet owners, veterinarians, health care providers and pharmacists that pets are at risk of illness and death when exposed to topical pain medications containing the nonsteroidal anti-inflammatory drug (NSAID) flurbiprofen. People using these medications should use care when applying them in a household with pets, as even very small amounts could be dangerous to these animals. The FDA received reports of cats in two households that became ill or died after their owners used topical medications containing flurbiprofen on themselves to treat muscle, joint, or other pain. The pet owners had applied the cream or lotion to their own neck or feet, and not directly to the pet, and it is not known exactly how the



cats became exposed to the medication. The products contained the NSAID flurbiprofen and the muscle relaxer cyclobenzaprine, as well as other varying active ingredients, including baclofen, gabapentin, lidocaine, or prilocaine.

**BACKGROUND:** Two cats in one household developed kidney failure and recovered with veterinary care. Two cats in a second household developed signs that included reluctance to eat, lethargy, vomiting, melena (black, tarry, bloody stools), anemia, and dilute urine. These two cats died despite veterinary care. A third cat in the second household also died after the owner had stopped using the medication. Veterinarians performed necropsies on the three cats that died and found evidence in the kidneys and intestines that were consistent with NSAID toxicity.

**RECOMMENDATION:** FDA recommends that people who use topical medications containing flurbiprofen take care to prevent their pets from being exposed to them, even in ways that may seem unlikely to cause problems. Health care providers who prescribe topical pain medications containing flurbiprofen, and pharmacists who fill these prescriptions, should advise patients with pets to take care to prevent exposure of the pet to the medication.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm443386.htm>

## Mucinex Fast-MAX Products: Recall - Incorrect Labeling

[Posted 04/22/2015]

**ISSUE:** RB (formerly Reckitt Benckiser) has recalled certain lots of liquid bottles of Mucinex Fast-MAX Night Time Cold & Flu; Mucinex Fast-MAX Cold & Sinus; Mucinex Fast-MAX Severe Congestion & Cough and Mucinex Fast-MAX Cold, Flu & Sore Throat because the over-the-counter medications, which correctly label the product on the front of the bottle and lists all active ingredients, may not have the correct corresponding drug facts label on the back. This mislabeling could cause the consumer to be unaware of side effects and/or risks associated with the ingestion of certain product ingredients which include acetaminophen, dextromethorphan, guaifenesin, phenylephrine and/or diphenhydramine.

Consumers could take a product with undeclared levels of acetaminophen, dextromethorphan, guaifenesin, phenylephrine and/or diphenhydramine. Consumers would not be adequately warned of side effects which could potentially lead to health complications requiring urgent medical intervention, particularly in the case of acetaminophen use in people with liver impairment.

**BACKGROUND:** RB is notifying its distributors and customers by direct correspondence. See the press release for a listing of affected product lot numbers.

**RECOMMENDATION:** RB is asking consumers to responsibly dispose of any unused product in accordance with the following recommended guidance for drug disposal in your household trash:

- Mix liquid medicines with an unpalatable substance such as kitty litter or used coffee grounds;
- Place the mixture in a container such as a sealed plastic bag; and
- Throw the container in your household trash.

Consumers who have purchased this product can also contact the RB MUCINEX FAST-MAX recall toll free number at 1-888-943-4215 between the hours of 8:00 a.m.- 8:00 p.m eastern standard time with any questions or to speak with a representative, and should refer to [www.mucinex.com/recall](http://www.mucinex.com/recall) for the accurate related drug facts information. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm444082.htm>

## Bupivacaine HCl Injection by Hospira: Recall - Iron Oxide Particulate In Glass Vials

**[Posted 04/24/2015]**

**ISSUE:** Hospira issued a voluntary recall of one lot of Preservative-Free Bupivacaine HCl Injection, USP, 0.5% (5 mg/mL), 30 mL Single-dose (NDC: 0409-1162-02, Lot 38-515-DK, Expiry 1FEB2016) due to one confirmed customer complaint of orange and black, visible particles embedded and free floating within a single-dose glass teartop vial. The particles were identified as iron oxide. This recall is being carried out to the user level (both human and veterinary). Risk factors associated with particulate include the potential for particulate to be injected and/or therapy may be delayed. If smaller pieces of the particulate break off and become free floating within the solution, it may be injected into the patient. Injected particulate may result in local inflammation, low-level allergic or immune responses, granuloma formation or mechanical irritation of tissue, in particular in patients allergic or sensitive to iron oxide. In addition, therapy may be delayed if observation of particulate is not made until the point of care. This delay is likely to be of negligible clinical significance provided remediation is readily available.

**BACKGROUND:** The lot was distributed from July 2014 to September 2014. Hospira is currently working with its glass supplier and has initiated an investigation to determine the root cause and corrective and preventive actions.

**RECOMMENDATION:** Anyone with an existing inventory of the recalled lot should stop use and distribution, and quarantine the product immediately. Customers should notify all users in their facility. Customers who have further distributed the recalled product should notify any accounts or additional locations which may have received the recalled product and instruct them if they have redistributed the product to notify their accounts, locations or facilities to the user level (both human and veterinary). Hospira will be notifying its direct customers via a recall letter and is arranging for impacted product to be returned to Stericycle. For additional assistance, call Stericycle at 1-866-918-8770 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.

**Source:** U.S. Food and Drug Administration (FDA)

**Article Link:**

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm444384.htm>

## STUDIES and RECENT TOPICS

---

### Measure kids' medicines in metric units, not spoonfuls, doctors say

**March 30, 2015**

Children's liquid medicines should only be measured in metric units to avoid overdoses common with teaspoons and tablespoons, U.S. pediatricians say. Tens of thousands of kids wind up in emergency rooms after unintentional medicine overdoses each year, and the cause is often badly labeled containers or unclear directions, said Dr. Ian Paul, a pediatrician at Penn State Milton S. Hershey Children's Hospital and lead author of new metric dosing guidelines from the American Academy of Pediatrics (AAP).

**Article Link:**

<http://www.reuters.com/article/2015/03/30/us-kids-medicines-dosing-idUSKBN0MQ09K20150330>

**Source:** reuters.com

### Medieval Remedy Found to be Highly Effective Against MRSA

**March 31, 2015**

Could a centuries-old remedy help treat modern-day bacteria, Methicillin-resistant Staphylococcus (MRSA)? While it sounds far-fetched, there is truth to the concept. British researchers recently found that a thousand-year-old Anglo-Saxon treatment for eye infections works as an antibiotic against MRSA. MRSA kills more than 5,000 people each year in the U.S.

**Article Link:** [http://www.dddmag.com/news/2015/03/medieval-remedy-found-be-highly-effective-against-mrsa?et\\_cid=4492933&et\\_rid=349712234&location=top](http://www.dddmag.com/news/2015/03/medieval-remedy-found-be-highly-effective-against-mrsa?et_cid=4492933&et_rid=349712234&location=top)

**Source Link:** dddmag.com

### Safe but inadequate: Tylenol flunks back pain test

**March 31, 2015**

Tylenol and other products containing acetaminophen do little or nothing to help lower back pain or arthritis, a new report finds. Patients might do better with stretching and exercise, the Australian researchers report. They don't recommend that people move on to stronger drugs such as opioids.

**Article Link:**

<http://www.today.com/health/safe-inadequate-tylenol-flunks-back-pain-test-t12306>

**Source:** today.com

## Opioid Misuse In Chronic Pain Patients Is Around 25%, New Study Shows

April 1, 2015

Various studies on problematic opioid use in chronic pain patients have been conducted over the years, but many of them have failed to clearly define misuse, abuse and addiction. One group of researchers believe they've uncovered an updated review of this topic with definitions of their own.

**Article Link:** [http://www.forbes.com/fdc/welcome\\_mjx.shtml](http://www.forbes.com/fdc/welcome_mjx.shtml)

**Source Link:** forbes.com

## Questions persist about sexual effects of baldness drug

April 1, 2015

A review of 34 clinical trials on a popular drug to treat hair loss in men found that none of the studies adequately reported on sexual side effects, researchers said. The findings raise serious questions about whether the drug -- known as finasteride and marketed as Propecia and Proscar, among other names -- is safe, said the report by scientists at Northwestern University, published in the Journal of the American Medical Association (JAMA) Dermatology on Wednesday.

**Article Link:** <http://news.yahoo.com/questions-persist-sexual-effects-baldness-drug-001609990.html>

**Source Link:** yahoo.com

## 1 in 5 Americans Take Drugs Every Day to Relax: Survey

April 1, 2015

Chilling out at the end of the day is harder for some Americans than others. According to a Gallup poll, 18.9 percent of Americans use a mood-altering drug almost every day to relax. Residents of West Virginia top the list at 28.1 percent followed by people living in Rhode Island at 25.9 percent.

**Article Link:** <http://www.newsmax.com/Health/Health-News/mood-altering-drug-relax-survey/2015/04/01/id/635815/>

**Source Link:** newsmax.com

## FDA Targets Opioid Drug Abuse With Guidelines Aimed At Manufacturers

April 1, 2015

The Food and Drug Administration (FDA) announced Wednesday it'll help manufacturers develop abuse-deterrent opioid drugs. "The science of abuse-deterrent medication is rapidly evolving, and the FDA is eager to engage with manufacturers to help make these medications

available to patients who need them,” Dr. Margaret A. Hamburg, the FDA’s commissioner, said in a press release. “We feel this is a key part of combating opioid abuse. We have to work hard with industry to support the development of new formulations that are difficult to abuse but are effective and available when needed.”

**Article Link:**

<http://www.medicaldaily.com/fda-targets-opioid-drug-abuse-guidelines-aimed-manufacturers-327852>

**Source:** medicaldaily.com

## America's Got a New Superbug to Fight

**April 2, 2015**

Wash your hands. Meet America’s latest superbug: Shigella sonnei. It’s a strain of bacteria that causes severe diarrhea in about half a million people in the U.S. each year. Most of the time, it’s treated effectively with an antibiotic called Cipro. But that’s changing, and it’s bad news.

**Article Link:**

<http://www.bloomberg.com/news/articles/2015-04-02/health-america-s-got-a-new-superbug-to-fight>

**Source:** Bloomberg.com

## New Thinking on Sinus Infections

**April 6, 2015**

Waiting for an infection to go away on its own works almost as well as antibiotics. Many people with spring allergies might also suffer with symptoms of another ailment—the facial pain, fever and nasal congestion that go with sinusitis.

**Article Link:**

<http://www.wsj.com/articles/new-thinking-on-sinus-infections-1428356464>

**Source:** wsj.com

## New Guidelines Would Greatly Boost Number of Young People on Statins

**April 6, 2015**

If all doctors followed new cholesterol guidelines aimed at children, almost half a million Americans aged 17 to 21 would be prescribed a cholesterol-lowering statin drug, a new study predicts.

In 2011, the U.S. National Heart, Lung, and Blood Institute (NHLBI) issued new guidelines on reducing heart disease in adolescents and young adults. Those guidelines recommended that all

people aged 17 to 21 get their blood levels of cholesterol checked, and statin treatment be initiated if cholesterol was at a certain level.

**Article Link:**

<http://consumer.healthday.com/cardiovascular-health-information-20/heart-stroke-related-stroke-353/new-guidelines-would-greatly-boost-number-of-young-people-on-statins-698074.html>

**Source Link:** healthday.com

## Study: weight-loss supplements contain amphetamine-like ingredients

**April 7, 2015**

A handful of weight-loss and sports supplements contain a never-before-tested ingredient that's closely related to amphetamines – not the plant extract indicated on their label, according to a Harvard-led study published online today by the journal Drug Testing and Analysis.

**Article Link:**

[http://www.usatoday.com/story/news/2015/04/07/weight-loss-supplements-amphetamines-sports/25380525/?utm\\_source=feedblitz&utm\\_medium=FeedBlitzRss&utm\\_campaign=usatoday-newstopstories](http://www.usatoday.com/story/news/2015/04/07/weight-loss-supplements-amphetamines-sports/25380525/?utm_source=feedblitz&utm_medium=FeedBlitzRss&utm_campaign=usatoday-newstopstories)

**Source:** usatoday.com

## Erectile dysfunction drugs vary in effectiveness, side effects

**April 7, 2015**

Viagra is the most effective treatment for erectile dysfunction, but it also has a higher rate of side effects than other options, according to an analysis of more than 150 trials. Viagra is known generically as sildenafil. Men concerned about possible side effects of Viagra like headaches, flushing, indigestion and nasal congestion may want to start on Cialis, which is known generically as tadalafil, researchers report in European Urology. If that's not effective, men in some countries can try Zydena (udenafil).

**Article Link:**

<http://www.reuters.com/article/2015/04/07/us-ed-drugs-profiles-idUSKBN0MY1TT20150407>

**Source Link:** reuters.com

## Erectile dysfunction drugs may help fight throat, neck cancer, study shows

**April 7, 2015**

MIAMI Researchers have discovered that the little blue and yellow pills that have boosted men's sex lives for more than two decades may actually someday help fight everything from liver disease and Alzheimer's to multiple sclerosis and cancer.

**Article Link:**

<http://www.latimes.com/nation/sns-tns-bc-med-ed-drugs-20150407-story.html>

**Source:** latimes.com

## Migraine Drug May Up Risk of Eating Disorders in Some Teens

**April 9, 2015**

A new report has linked a migraine medication to increased odds of eating disorders in some teens. The drug in question is called topiramate (Topamax). It's an established migraine drug for adults that was just approved for use in teens in 2014. Appetite reduction and weight loss are common side effects of the drug, according to the report authors.

**Article Link:**

<http://consumer.healthday.com/mental-health-information-25/anorexia-news-28/migraine-medicine-may-up-risk-of-eating-disorders-in-teens-698166.html>

**Source Link:** healthday.com

## FDA warns of liver injury from muscle-building supplement

**April 13, 2015**

The Food and Drug Administration is warning consumers to avoid dietary supplements sold by a Las Vegas company because they may contain anabolic steroids that can cause liver damage. The agency said it is investigating Tri-Methyl Xtreme supplements after three reported injuries from users in California, New Jersey and Utah.

**Article Link:**

[http://www.bostonherald.com/business/business\\_markets/2015/04/fda\\_warns\\_of\\_liver\\_injury\\_from\\_muscle\\_building\\_supplement](http://www.bostonherald.com/business/business_markets/2015/04/fda_warns_of_liver_injury_from_muscle_building_supplement)

**Source Link:** bostonherald.com

## Baxter again having to recall saline solution as shortage persists

**April 13, 2015**

Just weeks after recalling three lots of 0.9% sodium chloride injection amounting to nearly 600,000 units, Baxter (\$BAX) has recalled 8 more lots, adding further to the national shortage of saline. Last time the problem was leaky bags. This time the drugmaker says there is a problem with the chance for particulate in the bags. The FDA also announced the recall in a MedWatch notice.

**Article Link:**

<http://www.fiercepharmamanufacturing.com/story/baxter-again-having-recall-saline-solution-shortage-persits/2015-04-13>

**Source Link:** fiercepharmamanufacturing.com



## Adolescent abuse of prescription, OTC drugs remains an issue

**April 13, 2015**

Prescription and over-the-counter medications were the second most abused drugs among high school students, according to survey results published by the National Institute on Drug Abuse. In the Monitoring the Future 2014 survey, conducted by researchers at the University of Michigan, 6.8% of high school seniors reported nonmedical use of the amphetamine Adderall, 4.8% used Vicodin (acetaminophen and hydrocodone bitartrate, Abbott Laboratories), and 3.3% used OxyContin (oxycodone hydrochloride, Purdue Pharma).

**Article Link:**

<http://www.healio.com/pediatrics/adolescent-medicine/news/online/%7Bd5381046-f868-4a5d-b5f9-09e8efe5be83%7D/adolescent-abuse-of-prescription-otc-drugs-remains-an-issue>

**Source Link:** healio.com

## Mylan settles Viagra patent litigation with Pfizer

**April 13, 2015**

Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved. Mylan said on Monday that the settlement would allow it to launch Sildenafil Citrate by December 2017, or sooner under certain conditions, subject to approval by the U.S. Food and Drug Administration.

**Article Link:**

<http://www.reuters.com/article/2015/04/13/us-mylan-litigation-pfizer-idUSKBN0N423K20150413>

**Source Link:** reuters.com

## Pharmacists Key to Whether Patients Take Blood Thinners

**April 14, 2015**

Millions of older Americans are prescribed a blood thinner to help reduce the stroke risks associated with a dangerous irregular heart beat known as atrial fibrillation. A new study finds that even though a large percentage fail to take the potentially life-saving medications as prescribed, the intervention of their local pharmacist might help.

**Article Link:**

<http://consumer.healthday.com/cardiovascular-health-information-20/heart-stroke-related-stroke-353/pharmacists-key-to-whether-patients-take-their-blood-thinners-698301.html>

**Source Link:** healthday.com

## Having Both Depression And Type 2 Diabetes Increases Dementia Risk

April 15, 2015

Adults who have either depression or type 2 diabetes may have an increased risk of developing dementia, and the risk may be even higher for people who have both conditions, according to a new study.

**Article Link:** [http://www.huffingtonpost.com/2015/04/18/dementia-risk-factors\\_n\\_7088168.html?ncid=txtlnkusaolp00000592](http://www.huffingtonpost.com/2015/04/18/dementia-risk-factors_n_7088168.html?ncid=txtlnkusaolp00000592)

**Source Link:** [huffingtonpost.com](http://huffingtonpost.com)

## FDA Panel Wants HF Warning on Gliptin Drugs

April 15, 2015

An FDA advisory committee urged new labeling information to warn about heart failure risk with saxagliptin (Onglyza) and still-unclear risk with alogliptin (Nesina). All but one of 15 members of the agency's Endocrinologic and Metabolic Drugs Advisory Committee voting on saxagliptin said that evidence of increased risk of heart failure and allcause mortality from a large trial warranted label revisions, to spell out those risks.

**Article Link:**

<http://www.medpagetoday.com/Cardiology/Diabetes/51003>

**Source Link:** [medpagetoday.com](http://www.medpagetoday.com)

## Common heartburn drugs linked to kidney failure in the elderly

April 16, 2015

Older patients taking drugs known as proton pump inhibitors, a common remedy for heartburn and acid reflux, are two times more likely to be hospitalized with kidney failure than peers who don't take the pills, a study finds.

**Article Link:** <http://news.yahoo.com/common-heartburn-drugs-linked-kidney-failure-elderly-201133399.html>

**Source link:** [yahoo.com](http://yahoo.com)

## Why Supposedly Abuse-Proof Pills Won't Stop Opioid Overdose Deaths

April 17, 2015

Oral pain pills containing opioid have become a big business, drawing in companies including Purdue Pharma, Pfizer PFE -0.43%, and Zogenix ZGNX +2.17%. But they've also become a huge public health problem, leading to record numbers of drug overdose deaths. In 2013, more than 16,000 people died of opiate analgesic drug overdoses, up from 4,000 a decade ago.

**Article Link:** [http://www.forbes.com/fdc/welcome\\_mjx.shtml](http://www.forbes.com/fdc/welcome_mjx.shtml)

**Source Link:** forbes.com

## Glaxo recalls flu vaccine due to potency problem

**April 17, 2015**

GlaxoSmithKline is recalling remaining doses of a popular four-in-one flu vaccine because of effectiveness problems. The company alerted U.S. customers Tuesday that the vaccine can lose potency over time and fail to adequately protect against some strains of the flu. The Flulaval Quadrivalent Thimerosal-free vaccine in prefilled syringes is designed to protect against four strains of influenza virus.

**Article Link:**

[http://hosted.ap.org/dynamic/stories/U/US\\_FLU\\_VACCINE\\_RECALL\\_GLAXOSMITHKLINE?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT](http://hosted.ap.org/dynamic/stories/U/US_FLU_VACCINE_RECALL_GLAXOSMITHKLINE?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT)

**Source link:** ap.org

## Studies: Merck drug Keytruda effective against 3 cancers

**April 19, 2015**

One of the hot new cancer immunotherapy drugs, Merck & Co.'s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia.

**Article Link:**

[http://hosted.ap.org/dynamic/stories/U/US\\_CANCER\\_IMMUNOTHERAPY\\_DRUGS?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT](http://hosted.ap.org/dynamic/stories/U/US_CANCER_IMMUNOTHERAPY_DRUGS?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT)

**Source Link:** ap.org

## Aspirin May Help Ward Off Gastro Cancers, Study Finds

**April 19, 2015**

Taking aspirin regularly over several years may help prevent gastrointestinal cancers, a new study suggests. There was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.

**Article Link:**

<http://consumer.healthday.com/general-health-information-16/aspirin-news-46/aspirin-appears-to-help-ward-off-gastro-cancers-698461.html>

**Source Link:** healthday.com

## Tylenol May Blunt Emotions, and Not Just Pain

April 20, 2015

Acetaminophen (Tylenol) is a popular pain reliever, but it may also blunt emotions, both positive and negative, a new study shows. In a randomized, controlled trial, 85 people took 1,000 milligrams of Tylenol or a placebo. After one hour, researchers showed them a selection of 40 images in random order. They ranged from the extremely pleasant (children laughing in a park with kittens, for example) to neutral (a rolling pin on a table) to extremely unpleasant (an overflowing toilet).

**Article Link:**

[http://well.blogs.nytimes.com/2015/04/20/tylenol-may-blunt-emotions-and-not-just-pain/?ref=health&\\_r=1](http://well.blogs.nytimes.com/2015/04/20/tylenol-may-blunt-emotions-and-not-just-pain/?ref=health&_r=1)

**Source Link:** nytimes.com

## Overdoses fell after 2 narcotic painkillers were taken off the market

April 20, 2015

Patients got fewer narcotic painkillers and overdoses declined after two problem drugs were removed from the market in 2010, a large study of insurance claims reported Monday. The researchers looked at changes in the use of painkillers after manufacturers stopped producing propoxyphene and the original form of OxyContin. Propoxyphene, sold as Darvon, was removed because of concerns about heart problems, and OxyContin was replaced with a tamper-resistant version because the original pill was easy for addicts to crush and snort or inject for a heroin-like high.

**Article Link:**

<http://www.latimes.com/science/sciencenow/la-sci-sn-abuse-deterrant-opioid-20150420-story.html>

**Source Link:** latimes.com

## Why researchers say fake and low-quality drugs are a 'global pandemic'

April 20, 2015

Fake and substandard drugs are responsible for tens of thousands of deaths around the globe each year, and the persistent lack of reliable medicines in poor countries threatens to roll back decades of efforts to combat malaria, tuberculosis, HIV/AIDS and other conditions, researchers said Monday. "The pandemic of falsified and substandard medicines is pervasive and underestimated, particularly in low- and middle-income countries where drug and regulatory systems are weak or non-existent," Jim Herrington, a University of North Carolina public health professor who co-edited a collection of articles on the topic published in the American Journal of Tropical Medicine and Hygiene, said in a statement.

**Article Link:** <http://www.washingtonpost.com/news/to-your-health/wp/2015/04/20/why-researchers-say-fake-and-low-quality-drugs-are-a-global-pandemic/>

**Source Link:** [washingtonpost.com](http://washingtonpost.com)

## Diet pill death from DNP: Could it happen here?

**April 22, 2015**

The story of Eloise Aimee Parry -- the young woman in the U.K. who died after taking toxic diet pills she bought online -- will hopefully serve as a cautionary tale for consumers to stay far away from any quick-fix weight-loss product available on the Internet. But the tragic case of this 21-year-old college student is also a stark reminder of how little control health officials in the U.S. and abroad have when it comes to regulating pharmaceuticals on the Internet.

**Article Link:**

<http://www.cbsnews.com/news/diet-pill-death-from-dnp-are-fda-safety-regulations-enough/>

**Source Link:** [cbsnews.com](http://cbsnews.com)

## NIH-funded study identifies OTC compounds that may replace damaged cells

**April 22, 2015**

Two over-the-counter (OTC) drugs, an antifungal and a steroid, already on the market may potentially take on new roles as treatments for multiple sclerosis (MS), according to a study partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

**Article Link:**

<http://www.pharmaceutical-business-review.com/news/nih-funded-study-identifies-otc-compounds-that-may-replace-damaged-cells-220415-4559425>

**Source Link:** [pharmaceutical-business-review.com](http://pharmaceutical-business-review.com)

## Recommended treatments for alcoholic hepatitis 'fail to keep patients alive'

**April 22, 2015**

Two key drugs recommended in international guidelines and used to treat alcoholic hepatitis are failing to increase patients' survival and leave death rates among patients "alarmingly high", researchers said on Wednesday. In a trial involving more than 1,000 patients, the generic medicines -- prednisolone and pentoxifylline -- were found to make no significant reduction in death rates over 28 days, over 90 days, or even over a year.

**Article Link:**

<http://www.reuters.com/article/2015/04/22/us-health-hepatitis-medicines-idUSKBN0ND2K120150422>

**Source Link:** [reuters.com](http://reuters.com)

## **Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States**

**April 22, 2015**

Novo Nordisk today announced that Saxenda® (liraglutide [rDNA origin] injection) is now available in the United States. Saxenda® is the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults. It is indicated in the United States as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >30 kg/m<sup>2</sup>) or who are overweight (BMI >27 kg/m<sup>2</sup>) in the presence of at least one weight-related comorbid condition.

**Article Link:** <http://www.prnewswire.com/news-releases/novo-nordisk-announces-saxenda-liraglutide-rdna-origin-injection-is-now-commercially-available-in-the-united-states-300069888.html>

**Source Link:** [prnewswire.com](http://prnewswire.com)

## RECALLS\*

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
<b>CLASS I</b>					
Drugs	0.9% Sodium Chloride Injection USP, 100 mL MINI-BAG Plus Container, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015, USA, Product Code 2B0043, NDC 0338-0553-18.	Lot #: P317891, P317842, Exp 05/15	Class I	Presence of Particulate Matter: Confirmed customer complaints received for the presence of blue plastic, identified as fragments of the frangible from the vial adapter.	Baxter Healthcare Corp
Drugs	MitoXANTRONE Injection, USP, (concentrate) 2 mg/mL, Rx Only. Hospira, Lake Forest, IL 60045, Product of Australia. Available in a) 20 mg/10 mL Multi Dose Vial (NDC: 61703-343-18); b) 25 mg/12.5 mL Multi Dose Vial (NDC: 61703-343-65); c) 30 mg/15 mL Multi Dose Vial (NDC: 61703-343-66).	LOTS DISTRIBUTED IN THE UNITED STATES: a) Lot: Z054636AA, Expiry: December 2014; Lot: A014636AA, Expiry: April 2015; Lot: A024636AB, Expiry: July 2015. b) Lot: A014645AA, Expiry: November 2015. c) Lot: A014643AA, Expiry April 2015.	Class I	Failed Stability Specifications: Product is subpotent and has out of specification known and unknown impurities.	Hospira Inc.
Drugs	University of Alabama Birmingham TPN Neonatal Starter Bag, compound vol: 100 ml, Trophamine 4% Dextrose 10%, sterile injectable, Rx only, compounded drug,	lot number 37-74529, EXP: 24 DEC 2014, Made on 15 DEC 2014, CAPS Rx: 37-74529-0-20-R, Disp ID: 37-	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	IV infusion bag packaged in a corrugated box. each container is lined with a polystyrene insert; CAPS, Allentown, PA	1124540			
Drugs	Rose Medical Center (CO) Neonate D10 Bridge, Trophamine 3% Dextrose 10%, Additives: heparin PF 0.5 unit(s)/ml, compound vol: 350 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74756, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74756-0-8-R, Disp ID: 37-1124668.	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Rose Medical Center (CO) Neonate D5 Bridge, Trophamine 3% Dextrose 5%, Additives: heparin PF 0.5 unit(s)/ml, compound vol: 350 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74755, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74755-0-2-R, Disp ID: 37-1124670.	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	The Medical Center of Aurora (CO) Neonate Starter 2% AA/D10W, Trophamine 2% Dextrose 10%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	Neonate Starter 2% AA/D10W, lot number 37-74705, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74705-0-2-R, Disp ID: 37-1124595	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Bridgeport Hospital (CT)TPN Neonatal	lot number 37-74654 Made on	Class I	Non-Sterility: Out of specification results	Central Admixture



Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Standard Solution, Trophamine 6% Dextrose 10%, Additives: heparin PF 0.5 unit(s)/ml, Calcium Gluconate 4mEq/L, compound vol: 150 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74654-0-4-R, Disp ID: 37-1124511		for the sterility test for microbial contamination.	Pharmacy Services, Inc.
Drugs	Adventist Hinsdale Hospital (IL) Neonatal Starter: Troph 4%Dex5% ,Trophamine 4% Dextrose 5%, Additives: heparin PF 0.5 unit(s)/ml, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74764, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74764-0-2-R, Disp ID: 37-1124734	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Adventist Hinsdale Hospital (IL) Neonatal Starter: Troph 2% Dex10%, Trophamine 2% Dextrose 10%, Additives: heparin PF 0.5 unit(s)/ml, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74765, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74765-0-1-R, Disp ID: 37-1124732	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Advocate Good Samaritan Hospital (IL) TPN Dextrose 5% Trophamine 2%,	lot number 37-74661 Made on 15 DEC 2014, EXP 24 DEC	Class I	Non-Sterility: Out of specification results for the sterility test for microbial	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Trophamine 5% Dextrose 2%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	2014, CAPS Rx: 37-74661-0-4-R, Disp ID: 37-1124589		contamination.	
Drugs	Advocate Good Samaritan Hospital (IL) TPN Dextrose 10% Trophamine 2%, Trophamine 2% Dextrose 10%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74662 Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74662-0-4-R, Disp ID: 37-1124593	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Methodist Hospital Northlake (IN) Neo Starter TPN D5, AA2, Trophamine 2% Dextrose 5%, Additives: heparin PF 100 units/mL, 50 units/dL, Calcium Gluconate 0.46 mEq/mL, 200 mg/dL, compound vol: 300 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74767, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74767-0-3-R, Disp ID: 37-1124457	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Olathe Medical Center (KS) NICU TPN Starter: Ingredients per 80 ml, Trophamine 3g Dextrose 10%, Additives: Calcium Gluconate 250mg,	lot number 37-74547, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74547-0-1-R,	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	Disp ID: 37-1124708			
Drugs	Holy Cross Hospital (MD) AA3%TPN Neonatal Day 1 Bag, Trophamine 10%/3% Dextrose 70%/10%, Additives: Calcium Gluconate 0.46 mEq/mL, 5mEq, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74779, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74779-0-10-R, Disp ID: 37-1124608	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Sinai Hospital (MD) TPN Neonatal Day 1 Bag, Trophamine 10 g, Dextrose 25 g, Additives: Calcium Gluconate 1500 mg, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74693, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74693-0-4-R, Disp ID: 37-1124640	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Walter Reed Natl Mil Med Ctr (MD) Stock TPN D10% without Ca, Trophamine 12g, Dextrose 20g, compound vol: 200 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in	lot number 37-74711, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74711-0-5-R, Disp ID: 37-1124477	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.				
Drugs	Walter Reed Natl Mil Med Ctr (MD) Stock TPN D10% with Ca, Trophamine 12g, Dextrose 20g, Additives: Calcium Gluconate 8mEq, compound vol: 200 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74712, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74712-0-1-R, Disp ID: 37-1124468	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Providence Hospital Southfield (MI) Neonate TPN Starter Bag, Trophamine 3g, Dextrose 10%, Additives: heparin PF 0.5 unit(s)/mL, Calcium Gluconate 600mg, compound vol: 150 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74680, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74680-0-6-R, Disp ID: 37-1124687	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	St Lukes East Lees Summit (MO) Protein Bag, Trophamine 5g, Dextrose 10%, Additives: Calcium Gluconate 4.65mEq, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is	lot number 37-74520, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74520-0-6-R, Disp ID: 37-1124617	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	lined with a polystyrene insert; CAPS, Allentown, PA.				
Drugs	Truman Medical Center Lakewood (MO) Starter TPN, Trophamine 5.25g, Dextrose 10%, Additives: Calcium Gluconate 4.8mEq, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74700, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74700-0-1-R, Disp ID: 37-1124575	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Truman Medical Center Lakewood (MO) Trophamine UAC Solution, Trophamine 3.2g, compound vol: 100 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74699, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74699-0-5-R, Disp ID: 37-1124574	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Hackensack University Med Ctr (NJ) 5% Dextrose Neonatal Solution, Trophamine 3%, Dextrose 5%, Additives: Calcium Gluconate 0.46mEq/mL, 7mEq/L, compound vol: 150 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74503, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74503-0-10-R, Disp ID: 37-1124660	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Robert Wood Johnson	lot numbers 37-	Class I	Non-Sterility: Out of	Central

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	University (NJ) Neonatal Starter 10% Dextrose, Trophamine 5%, Dextrose 10%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	74792 and 37-74635, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74792-0-2-R and CAPS Rx: 37-74635-0-2-R, Disp ID: 37-1124677 and Disp ID: 37-1124679		specification results for the sterility test for microbial contamination.	Admixture Pharmacy Services, Inc.
Drugs	Robert Wood Johnson University (NJ) Neonatal Starter 5% Dextrose, Trophamine 5%, Dextrose 5%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74634, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74634-0-2-R, Disp ID: 37-1124681	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Virtua West Jersey Voorhees (NJ) TPN Neonatal Starter Bag, Trophamine 3% Dextrose 10%, Additives: heparin PF 0.5 unit(s)/ml, Calcium Gluconate 200mg/dL, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74914, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74914-0-20-R, Disp ID: 37-1124768	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Abington Memorial Hospital (PA) TPN Neonatal Starter 0.6-0.99 Kg, Amino Acids, Neonate 5g, Dextrose	lot number 37-74652, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx:	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	7.5%, 250 ml, Additives: heparin PF 125 unit(s)/ml, Calcium Gluconate 500mg, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	37-74652-0-4-R, Disp ID: 37-1124739			
Drugs	Abington Memorial Hospital (PA) TPN Neonatal Starter 0.4-0.599 Kg, Amino Acids, Neonate 3g, Dextrose 5%, 150 ml, Additives: heparin PF 75 units, Calcium Gluconate 300mg, compound vol: 150 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74653, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74653-0-1-R, Disp ID: 37-1124735	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Abington Memorial Hospital (PA) TPN Neonatal Starter > 1Kg, Amino Acids, Neonate 12.5g, Dextrose 10%, 500 ml, Additives: heparin PF 250 units, Calcium Gluconate 1250mg, compound vol: 500 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74651, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74651-0-6-R, Disp ID: 37-1124745	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
Drugs	Lankenau Hospital (PA) TPN Neonatal Starter Bag, Trophamine 2.5%, Dextrose 10%, Additives: heparin PF 62.5 units, Calcium Gluconate 500mg, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA	lot number 37-74671, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74671-0-6-R, Disp ID: 37-1124546	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Bayshore Medical Center (TX) 10% Dextrose Starter Neo TPN, Trophamine 2.4% , Dextrose 10%, Additives: heparin PF 1 unit(s)/ml, Calcium Gluconate 2.3mEq/dL, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74776, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74776-0-3-R, Disp ID: 37-1124585	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Bayshore Medical Center (TX) 5% Dextrose Starter Neo TPN, Trophamine 2.4% , Dextrose 5%, Additives: heparin PF 1 unit(s)/ml, Calcium Gluconate 2.3mEq/dL, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74775, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74775-0-3-R, Disp ID: 37-1124582	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.



Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
Drugs	Texas Health Presbyterian Dallas Neonatal Admit TPN 4 GM, Trophamine 4g/dL, Dextrose 10%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74768, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74768-0-5-R, Disp ID: 37-1124563	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Spotsylvania Regional Med Ctr (VA) TPN Neonatal Starter Bag with Calcium, Trophamine 5 gm, Dextrose 10%, Additives: Calcium Gluconate 0.46 mEq/mL, 750mg, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74695, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74695-0-2-R, Disp ID: 37-1124634	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Spotsylvania Regional Med Ctr (VA) TPN Neonatal Starter Bag, Trophamine 5 gm, Dextrose 10%, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74696, Made on 15 DEC 2014, EXP 24 DEC 2014, CAPS Rx: 37-74696-0-2-R, Disp ID: 37-1124636	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
Drugs	Virginia Hospital Center (VA) TPN Neonatal Day 1 Bag, Trophamine 5.5 gm,	lot number 37-74714, Made on 15 DEC 2014,	Class I	Non-Sterility: Out of specification results for the sterility test	Central Admixture Pharmacy

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Dextrose 10%, Additives: Calcium Gluconate 0.46mEq/mL, 600 mg, compound vol: 250 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	EXP 24 DEC 2014, CAPS Rx: 37-74714-0-12-R, Disp ID: 37-1124493		for microbial contamination.	Services, Inc.
Drugs	Practi-0.9% Sodium Chloride, 50 mL, 100 mL, 250 mL, 500 mL, and 1000 mL bags, Product of China, Wallcur, San Diego, CA, 92111, USA; Wallcur Practi Products for Clinical Simulation; NDCs 5108-0954-75, 5108-0954-71, 5108-0954-72, 5108-0954-74, 5108-0954-73.	No unique lot number on product; all Practi-0.9% Sodium Chloride is subject to recall.	Class I	Non-sterility: Product is made in a non-sterile facility and is not intended for use in humans or animals.	Wallcur Incorporated
Drugs	Children's Hospital Colorado Springs TPN Neonate Starter Bag 4% AA/10% DEX, Trophamine 4% Dextrose 10%, compound vol: 500 ml, sterile injectable, Rx only, compounded drug, IV infusion bag packaged in a corrugated box, each container is lined with a polystyrene insert; CAPS, Allentown, PA.	lot number 37-74731, EXP 24 DEC 2014, Made on 15 DEC 2014, CAPS Rx: 37-74731-0-10-R, Disp ID: 37-1124452.	Class I	Non-Sterility: Out of specification results for the sterility test for microbial contamination.	Central Admixture Pharmacy Services, Inc.
<b>CLASS II</b>					
Drugs	Hydroxocobalamin Injection Solution 1 mg/mL Inj., Rx, compounded by American Specialty Pharmacy, Plano, TX 75075 214-919-2090. NDC 99999-9994-27	Lot #10082014@10	Class II	Presence of Particulate Matter; preservative may not have dissolved completely or precipitated out of product	American Specialty Pharmacy

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
Drugs	B-Lipo, 30 Capsules, Manufactured by KM DALI, Kunming, China for Bethel Nutritional Consulting, Inc. 599 West 190th Street, Suite #1 NYC, NY 10040.	Lot #: 20213, Exp 12/22/2016.	Class II	Marketed without an Approved NDA/ANDA; found to contain Lorcaserin, a controlled substance used for weight loss	Bethel Nutritional Consulting, Inc
Drugs	Haloperidol Decanoate Injection, 100 mg/mL, For Intra Muscular Use Only, 1 mL single dose vials (NDC 67457-409-00) packaged in cartons of five (NDC 67457-409-13), Rx only, Manufactured in India for: Mylan Institutional LLC Rockford, IL 61103	Lot 7602281, Exp 4/16; Lot 7602283, Exp 4/16	Class II	Lack of Assurance of Sterility; due to leaking vials	Mylan Institutional LLC
Drugs	Haloperidol Decanoate Injection, 50 mg/mL, For Intra Muscular Use Only, 1 mL single dose vials (NDC 67457-410-00) packaged in cartons of ten (NDC 67457-410-13), Rx only, Manufactured in India for: Mylan Institutional LLC Rockford, IL 61103	Lot 7602368, Exp 7/16; Lot 7602369, Exp 7/16	Class II	Lack of Assurance of Sterility; due to leaking vials	Mylan Institutional LLC
Drugs	0.9% Sodium Chloride Injection, USP, 500 mL in VIAFLEX Plastic Container, Rx only, Manufactured by Baxter Healthcare Corp., North Cove, North Carolina Facility Highway 221 North, Marion, NC 28752 for Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC 0338-0049-03	Lot #: C929844, Exp 5/31/2015; C926873, Exp 4/30/2015; C928630, Exp 4/30/2015.	Class II	Lack of Assurance of Sterility. Complaints were received of missing closures and/or leaks which may compromise product sterility.	Baxter Healthcare Corp.
Drugs	5% Dextrose Injection, USP, 1000mL in VIAFLEX	Lot #: C926899, Exp 7/31/2015	Class II	Lack of Assurance of Sterility. Complaints	Baxter Healthcare

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Plastic Container, Rx only, Manufactured by Baxter Healthcare Corp., North Cove, North Carolina Facility Highway 221 North, Marion, NC 28752 for Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC 0338-0017-04			were received of missing closures and/or leaks which may compromise product sterility.	Corp.
Drugs	KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vials, I.V/I.M. USE, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-3795-01 --- Also labeled under NOVAPLUS label NDC 0409-3795-49	NDC 0409-3795-01, Lot number: 25-047-DK, 25-048-DK, Exp 1JAN2015; Lot number 26-151-DK, Exp. Date:1FEB2015; Lot number: 28-059-DK, 28-071-DK, 28-072-DK, 28-479-DK, 28-480-DK, Exp. Date:1APR2015; Lot number: 29-556-DK, 29-557-DK, Exp. Date:1MAY2015 ; Lot number: 35-232-DK, 35-233-DK, 35-234-DK, 35-501-DK, Exp. Date:1NOV2015 ; Lot number: 36-341-DK, 36-342-DK, 36-343-DK, 36-353-DK, 36-429-DK, 36-430-DK, Exp. Date:1DEC2015; Lot number: 37-141-DK, 37-142-DK, 37-144-DK,	Class II	Crystallization	Hospira Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
		37-145-DK, 37-353-DK, Exp. Date:1JAN2016; Lot number: 38-141-DK, 38-143-DK, Exp. Date:1FEB2016; Lot number: 39-014-DK, 39-104-DK, Exp. Date:1MAR2016 ; Lot number: 40-301-DK, 40-536-DK, 40-537-DK, 40-544-DK, 40-548-DK, Exp. Date:1APR2016; Lot number: 41-078-DK, Exp. Date:1MAY2016 ; Lot number: 42-207-DK, 42-253-DK, Exp. Date:1JUN2016; Lot number: 45-358-DK, 45-359-DK, Exp. Date:1SEP2016; Lot number: 46-043-DK, 46-044-DK, 46-047-DK, Exp. Date:1OCT2016 AND NOVAPLUS LABEL NDC 0409-3795-49, Lot number: 27-101-DK, Exp. Date:1MAR2015 ; Lot number: 35-229-DK, Exp. Date:1NOV2015 ; Lot number: 36-217-DK, 36-218-DK, Exp.			

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
		Date:1DEC2015 and Lot number: 40-534-DK, Exp. Date:1APR2016			
Drugs	KETOROLAC Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Fill Single-dose Vials, I.V./I.M. USE, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-3796-01 ---- ALSO labeled under NOVAPLUS label NDC 0409-3796-49	NDC 0409-3796-01, Lot number: 26-098-DK, Exp. Date:1FEB2015; Lot number: 29-239-DK, 29-240-DK, Exp. Date:1MAY2015 ; Lot number: 34-540-DK, Exp. Date:1OCT2015; Lot number: 37-037-DK, 37-038-DK, 37-147-DK, 37-148-DK, 37-228-DK, 37-282-DK, Exp. Date:1JAN2016; Lot number: 41-282-DK, 41-284-DK, Exp. Date:1MAY2016 ; Lot number: 44-076-DK, Exp. Date:1AUG2016 ; Lot number: 45-240-DK, Exp. Date:1SEP2016 and Lot number: 46-306-DK, Exp. Date:1OCT2016 AND NOVAPLUS labelNDC 0409-3796-49, Lot number: 26-097-DK, Exp. Date:1FEB2015.	Class II	Crystallization	Hospira Inc.
Drugs	KETOROLAC TROM 30 MG/ML INJ, 1 mL glass vials repackaged individually inside an	NDC 61786-0055-01, Lot # B00484449-100914, Lot #	Class II	Crystallization	RemedyRepack Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	amber glass bottle, packaged by RemedyRepack, Indiana, PA, mfg by Hospira, Inc. Lake Forest, IL NDC 61786-0055-01	B0062349-121914, Lot # B006655-011415; Expiration Date: 04/01/2016			
Drugs	Fomepizole Injection, 1.5 g/1.5 mL (1 g/mL), For Intravenous Infusion only, Rx only, Manufactured by: Emcure Pharmaceuticals Lt. for Sandoz Inc., Princeton, NJ 08540, NDC 0781-3182-73 and 0781-3182-84	Lot #: VFMA 029, VFMA 030, VFMA 031, VFMA 032 Exp 4/15; VFMA 033, Exp 7/2016; VFMA 034, Exp 10/2017.	Class II	Lack of Assurance of Sterility. A recent FDA inspection reported GMP violations potentially impacting product quality and sterility.	Navinta LLC
Drugs	GLIPIZIDE and METFORMIN HYDROCHLORIDE Tablets, USP, 2.5 mg/500 mg, 100 ct Bottles, Rx Only. Manufactured for: Heritage Pharmaceuticals Inc. Eatontown, NJ 07724, NDC: 23155-116-01.	Lot #:18020994, Expiry: October 2015; Lot #: 18021311, Expiry: November 2015.	Class II	Failed Impurities/Degradation Specifications: Out of specification for unknown impurity.	Heritage Pharmaceuticals, Inc.
Drugs	0.9% Sodium Chloride Injection, USP, 50 mL, VIAFLEX Plastic Container Multi Pack, Rx Only, Baxter Healthcare Corporation, Deerfield, IL , Product code 2B1308, NDC 0338-0049-31	Product code: 2B1308; Lot#: P316497, exp date: 10/2015	Class II	Lack of Assurance of Sterility; increased complaints received for leaks	Baxter Healthcare Corp
Drugs	Clinimix E 5/20 sulfite-free (5% amino-acid with electrolytes in 20% dextrose with calcium) Injection, 2000 mL in Dual Chamber Container, Rx Only, Baxter Healthcare Corporation, Deerfield, IL --- Product code 2B7722, NDC 0338-1125-04	Product code: 2B7722, Lot#: P306365, exp date: 08/31/2015	Class II	Lack of Assurance of Sterility; increased complaints received for leaks	Baxter Healthcare Corp

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
Drugs	Benzonatate Capsules, USP, 100 mg, 100 count (10X10), Rx only, Packaged and Distributed by: American Health Packaging Columbus, Ohio 43217 --- NDC 68084-214-01(carton) NDC 68084-214-11 (individual dose)	AHP lot number 145513, exp 6/2016	Class II	Failed Tablet/Capsule Specifications; recall initiated by manufacturer due to reports of wet capsules	American Health Packaging
Drugs	Minivelle (estradiol transdermal system) 0.05 mg/day, 8-count box, Rx only, Manufactured by Noven Pharmaceuticals, Inc., Miami, Florida 33186, Distributed by Noven Pharmaceuticals, LLC, Miami, Florida 33186, NDC 68968-6650-8	Lot # 76476; Exp 07/16	Class II	Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.	Noven Pharmaceuticals, Inc.
<b>CLASS III</b>					
Drugs	Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL) 25 x 5 mL Single Dose Vials, For Intravenous or Intramuscular Use, Preservative Free, Rx Only, Manufactured by: West-Ward Pharmaceuticals, Eatontown, NJ 07724, NDC 0641-6028-25.	Lot #: 113312, Exp 11/2015; 014315 Exp 01/2016	Class III	Failed Impurities/Degradation Specifications; 12 month stability testing.	West-Ward Pharmaceutical Corporation
Drugs	Fexofenadine HCl Tablets, USP, 60 mg, Allergy, Antihistamine, Indoor and Outdoor Allergies, Non-Drowsy, Original Prescription Strength, a) 60 count Bottles, NDC 0378-0781-91, b) 500 count Bottles, NDC 0378-0781-05, Manufactured by: Mylan	Lot #: 3047303, Exp 04/2015	Class III	Failed Impurities/Degradation Specifications: Routine stability testing yielded out of specification results for a related compound - a degradant of fexofenadine.	Mylan Pharmaceuticals Inc.



Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Pharmaceuticals Inc, Morgantown, WV, 26505, USA.				
Drugs	AIR COMPRESSED, Medical Air, USP, Rx Only. Matheson Tri-Gas, Inc., 150 Allen Road, Basking Ridge, NJ 07920. Available in A) E or 22 cu ft cylinder, NDC: 55037- 302-09; B) 40 cu ft cylinder, NDC: 55037- 302-10; C) 200 cu ft cylinder, NDC: 55037- 302-15; D) 220 cu ft cylinder, NDC: 55037- 302-16; E) 300 cu ft cylinder, NDC: 55037- 302-18, 55037-302-19, 55037-302-20.	A) Lot #: BAHC564281A, BAHC564281B, BAHC546288A, BAHC564288B, BAHC546288C, BAHC546288D, BAHC546288E, BAHC564307A, BAHC564314A, BAHC564329A. BAHC564329B, BAHC564329C, BAHC564329D, BAHC564329E, BAHC564344A, BAHC565005A, BAHC565006A, BAHC565013A, BAHC565015A, BAHC565015B, BAHC565015C, BAHC565015D, BAHC565029A, BAHC565035A. BAHC565035B, BAHC565035D; B) Lot #: BAHC564282A, BAHC564296A, BAHC564303A, BAHC564344A, BAJC565016A, BAHC565034A, BAHC565043A, BAHC565054A; C) Lot #: BAHC564269A, BAHC564275A, BAHC564282A, BAHC564288A, BAHC564296A,	Class III	Failed Impurities/Degradati on Specification; out of specification results for carbon dioxide	Matheson, Inc.

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
		BAHC564303A, BAHC564308A, BAHC564317A, BAHC564324A, BAHC564329A, BAHC564338A, BAHC564344A, BAHC564351A, BAHC565016A, BAHC565020A, BAHC565028A, BAHC565043A, BAHC565054A; D) Lot #: BAHC564365A; E) Lot #: BAHC564269A, BAHC564275A, BAHC564279A, BAHC564282A, BAHC564290A, BAHC564296A, BAHC564303A, BAHC564308A, BAHC564317, BAHC564324A, BAHC564329A, BAHC564350A, BAHC564356A, BAHC564365A, BAHC565005A, BAHC565006A, BAHC565013A, BAHC565020A, BAHC565029A, BAHC565042A, BAHC565054A.			
Drugs	PROMETHAZINE VC WITH CODEINE SYRUP, EACH 5 ml contains: Codeine Phosphate 10 mg, Promethazine Hydrochloride 6.25 mg, Phenylephrine Hydrochloride 5 mg,	Lot #: (a) L073D14A, Exp 07/31/15. Lot #: (b) L073D14B, Exp 07/31/15; 000002247, Exp 03/31/16; L063B14A, Exp	Class III	Failed Impurities/Degradation Specifications: A stability lot was out of specification for a known impurity at the 8 month Controlled Room	Qualitest Pharmaceuticals

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	alcohol 7%, (a) 4 fl oz bottle (NDC 0603-1588-54) and (b) 16 fl oz bottle (NDC 0603-1588-58) Rx only, Manufactured for QUALITEST PHARMACEUTICALS, HUNTSVILLE, AL 35811.	05/31/15		Temperature stability time-point.	
Drugs	Potassium Chloride, microencapsulated extended-release tablets, 20 mEq, blister card of 30/10 cards in a corrugated shipper, Rx only, Manufactured by Upsher-Smith Laboratories, Inc. Minneapolis, MN 55447 for Sandoz, Inc., Princeton, NJ 08540 Repackaged by Cardinal Health Zanesville, OH 43701	Lot #: 315004A, Exp 1/15/14; Lot #: 315620A, Exp 1/15/14	Class III	Labeling: Incorrect or Missing Package Insert: the package insert for the potassium chloride 8 mEq and 10 mEq strength instead of the potassium chloride 10 mEq and 20 mEq strength was packaged with the product.	Cardinal Health
Drugs	Bromfenac Ophthalmic Solution 0.09%, Rx Only. Mfg For: Apotex Corp., Weston, FL, 33326. Available in a) 1.7 mL Bottle, NDC: 60505-0595-5; b) 2 x 1.7 mL Bottles, NDC: 60505-0595-6; c) 2.5 mL Bottles, NDC: 60505-0596-4.	a) Lot #: KY8498, Expiry: 01/2016; b) Lot #: KY8496, Expiry: 01/2016; c) Lot #: MC5426, Expiry: 02/2016; Lot #: KZ2002, Expiry: 04/2016.	Class III	CGMP Deviations: Product excipient was not re-tested at the appropriate date.	Apotex Inc.
Drugs	Cartia XT (diltiazem HCl extended-release capsules, USP), Once-A-Day Dosage, 300 mg, 90-count bottles, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA --- NDC 62037-0600-90	Lot # 956000M, Exp. Aug 2016; UPC 3-6203760090-6	Class III	Presence of Foreign Substance; fine residue or dust identified as aluminum may be on exterior of the capsule shell	Actavis Laboratories, FL, Inc.
Drugs	Flurandrenolide Tape, USP, 4 mcg per sq cm, Rx Only. Distributed By:	A) Lots: 266142A, 843021,	Class III	Subpotent Drug: Flurandrenolide is subpotent.	Actavis Laboratories

Product Type	Product Description	Code info.	Class	Reason for Recall	Recalling firm
	Actavis Pharma, Inc., Parsippany, NJ 07054, Manufactured By: 3M Company, St. Paul, MN, 55144. Labeled as A) Cordran Tape, Small Rolls, 24 in x 3 in, NDC: 52544-044-24, B) Cordran Tape, Large Rolls, 80 in x 3 in, NDC: 52544-044-80, C) Haelan Tape (Fludroxycortide), Bulk Rolls, NDC: 55515-014-00.	845760, 853846, 893193, 900634; Expiry: JAN-2016. B) Lots: 266142D, 822241, 853847, 862000, 874337, 893209; Expiry: JAN-2016. C) Lot: 266142C; Expiry: JAN-2016.			
<b>VACCINES</b>					
Biologics	NONE				

\*Please refer to FDA website for further information; <http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm>

## CURRENT DRUG SHORTAGES‡

---

### Atracurium Injection

**Apr 01, 2015**

#### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including atracurium injection. West-Ward is not actively marketing atracurium.
- Hospira has atracurium available.
- Sagent has atracurium on shortage due to product recall.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=872>

**Source link:** <http://www.ashp.org>

### Leucovorin Calcium Injection

**Apr 02, 2015**

#### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired leucovorin calcium injection from Bedford in July 2014. West-Ward is not actively marketing leucovorin calcium injection at this time.
- Teva had leucovorin on shortage due to manufacturing delays.
- Fresenius Kabi has leucovorin on shortage due to increase demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=488>

**Source link:** <http://www.ashp.org>

### Leucovorin Calcium Injection

**Apr 02, 2015**

#### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired leucovorin calcium injection from Bedford in July 2014. West-Ward is not actively marketing leucovorin calcium injection at this time.
- Teva had leucovorin on shortage due to manufacturing delays.
- Fresenius Kabi has leucovorin on shortage due to increase demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=488>  
**Source link:** <http://www.ashp.org>

## Electrolyte Concentrate

Apr 02, 2015

### Reason for the Shortage

- American Regent has Nutrilite and Nutrilite on back order due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=488>

**Source link:** <http://www.ashp.org>

## Cefotaxime Injection

Apr 02, 2015

### Reason for the Shortage

- Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
- Baxter has Claforan on allocation due to increased demand.
- West-Ward cannot provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=826>

**Source link:** <http://www.ashp.org>

## Caffeine and Sodium Benzoate Injection

Apr 02, 2015

### Reason for the Shortage

- American Regent has caffeine and sodium benzoate injection on shortage due to manufacturing delays.
- American Regent is the sole manufacturer of caffeine and sodium benzoate injection.
- Caffeine citrate injection is not affected by this shortage

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=817>

**Source link:** <http://www.ashp.org>

## Trypan Blue 0.15% Ophthalmic Solution

Apr 03, 2015

### Reason for the Shortage

- Dutch Ophthalmic has MembraneBlue on shortage due to difficulty in obtaining raw materials.
- There are no other manufacturers of trypan blue.
- Dutch Ophthalmic has VisionBlue 0.06% ophthalmic solution available (NDC 68803-0612-10). VisionBlue is used as an adjunct in cataract surgery.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1145>

**Source link:** <http://www.ashp.org>

## Tobramycin Injection

Apr 03, 2015

### Reason for the Shortage

- Teva has tobramycin solution for injection on shortage due to manufacturing delays.
- Hospira has tobramycin on shortage due to manufacturing delays.
- Fresenius Kabi has tobramycin solution for injection on shortage due to increased demand.
- Pfizer acquired tobramycin injection from Akorn in early-May, 2011.
- Pfizer divested tobramycin injection to Mylan Institutional on December 6, 2013.
- Mylan Institutional has changed the NDC numbers of their tobramycin presentations.

### **Article Look:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=701>

**Source link:** <http://www.ashp.org>

## Sincalide Injection

Apr 03, 2015

### Reason for the Shortage

- Bracco Diagnostics has Kinevac on shortage due to manufacturing delays.
- There are no approved alternatives to Kinevac for the labeled indications.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1032>

**Source link:** <http://www.ashp.org>

## Secretin Injection

Apr 03, 2015

### Reason for the Shortage

- ChiRhoClin is qualifying a manufacturing site.
- ChiRhoClin has been working with FDA to release ChiRhoStim lot # 0636149. This lot was produced at a new manufacturing site that has not been approved by FDA. Please see the Dear Health Care Provider letter for additional information. ChiRhoClin anticipates the release of a new ChiRhoStim lot in 2015.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=913>

**Source link:** <http://www.ashp.org>

## Propranolol Injection

Apr 03, 2015

### Reason for the Shortage

- Ben Venue closed its plant in Bedford, Ohio in July 2014.
- Fresenius Kabi has propranolol injection on back order due to shortage of raw materials.
- Sandoz cannot provide a reason for the shortage.
- West-Ward has propranolol injection on shortage due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1091>

**Source link:** <http://www.ashp.org>

## Proparacaine Hydrochloride Ophthalmic Solution

Apr 03, 2015

### Reason for the Shortage

- Sandoz could not provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1147>

**Source link:** <http://www.ashp.org>



## Promethazine Injection

Apr 03, 2015

### Reason for the Shortage

- Teva states the shortage is due to manufacturing delays.
- West-Ward states the shortage was due to manufacturing delays. The company has also changed the NDC numbers for products that were formerly Baxter products.
- Hospira states the shortage is due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=654>

**Source link:** <http://www.ashp.org>

## Pantoprazole Injection

Apr 03, 2015

### Reason for the Shortage

- Pfizer has Protonix on shortage due to increased demand.
- Pfizer is the sole supplier of pantoprazole injection.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1153>

**Source link:** <http://www.ashp.org>

## Nimodipine Capsules

Apr 03, 2015

### Reason for the Shortage

- Caraco cannot provide a reason for the shortage.
- Teva discontinued nimodipine capsules in early-March, 2013.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=970>

**Source link:** <http://www.ashp.org>

## Lidocaine Topical 4% Solution

Apr 03, 2015

### Reason for the Shortage

- Hospira discontinued LTA Syringes kits on August 5, 2014 due to a business decision.

- Amphastar IMS has Laryng-O-Jets on shortage due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1128>

**Source link:** <http://www.ashp.org>

## Haloperidol Lactate Injection

**Apr 03, 2015**

### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including haloperidol lactate injection. West-Ward is not actively marketing haloperidol lactate at this time.
- Mylan Institutional could not provide a reason for the shortage.
- Sagent could not provide a reason for the shortage.
- Teva has haloperidol lactate on shortage due to manufacturing delays.
- Mylan Institutional acquired haloperidol lactate injection from Pfizer on December 6, 2013.
- Patriot Pharmaceuticals states the reason for the shortage was increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=527>

**Source link:** <http://www.ashp.org>

## Dipyridamole Injection

**Apr 03, 2015**

### Reason for the Shortage

- Teva has temporarily discontinued their 2 mL and 10 mL products in order to increase the package sizes.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=465>

**Source link:** <http://www.ashp.org>

## Cyanocobalamin Injection

Apr 03, 2015

### Reason for the Shortage

- American Regent has cyanocobalamin injection on shortage due to manufacturing delays.
- Fresenius Kabi has cyanocobalamin injection available.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=947>

**Source link:** <http://www.ashp.org>

## Vecuronium Bromide Injection

Apr 06, 2015

### Reason for the Shortage

- Hospira states the shortage is due to manufacturing delays.
- Teva states the shortage is due to manufacturing delays.
- Pfizer sold vecuronium injection to Mylan Institutional in December 2013.
- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in 2014.
- Caraco has vecuronium injection available.
- Sagent temporarily suspended the manufacture of vecuronium 10 mg and 20 mg vials.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=490>

**Source link:** <http://www.ashp.org>

## Tamsulosin Hydrochloride Capsules

Apr 06, 2015

### Reason for the Shortage

- Boehringer Ingelheim could not provide a reason for the shortage.
- Actavis and Zydus state the reason for the shortage is increased demand.
- Aurobindo is not marketing the 100 count size.
- Caraco cannot provide a reason for the shortage.
- Teva discontinued tamsulosin 0.4 mg capsules in April 2014.
- Par discontinued tamsulosin 0.4 mg capsules.
- Sandoz has tamsulosin on shortage due to increased demand for the product.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1112>

**Source link:** <http://www.ashp.org>

## Sumatriptan Succinate Injection

**Apr 06, 2015**

### Reason for the Shortage

- Sagent states the reason for the shortage is increased demand.
- GlaxoSmithKline could not provide a reason for the shortage.
- Pfizer has had Alsuma on shortage since September 2013 due to manufacturing issues.
- Zogenix sold Sumavel DosePro to Endo in 2014.
- Teva has temporarily suspended the production of sumatriptan injection.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1085>

**Source link:** <http://www.ashp.org>

## Moxifloxacin Injection

**Apr 06, 2015**

### Reason for the Shortage

- Merck cannot provide a reason for the shortage.
- Merck is the sole supplier of moxifloxacin intravenous presentations. Moxifloxacin tablets are not affected by this shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1151>

**Source link:** <http://www.ashp.org>

## Methylphenidate Hydrochloride Extended Release Oral Presentations

**Apr 06, 2015**

### Reason for the Shortage

- Mallinckrodt states the shortage was due to delay in obtaining raw materials.
- Teva introduced generic methylphenidate extended release capsules (CD) in late-September 2012, and these capsules are AB-rated to Metadate CD capsules.
- Actavis states the shortage of methylphenidate is due to increased demand. Actavis estimates a shortage of methylphenidate ER tablets will begin in December 2014 and last through 2nd quarter 2015.
- UCB states methylphenidate ER tablets were on shortage due to supply and demand.

- Janssen states the shortage of Concerta is due to increased demand. Janssen estimates a shortage of Concerta will begin in December 2014 and last through 2nd quarter 2015.
- Novartis discontinued Ritalin SR in October 2014.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1166>

**Source link:** <http://www.ashp.org>

## Hydroxychloroquine Sulfate Tablets

**Apr 06, 2015**

Reason for the Shortage

- Ranbaxy has hydroxychloroquine on shortage due to a regulatory issue.
- Sandoz states the hydroxychloroquine shortage is due to increased demand.
- Zydus could not provide a reason for hydroxychloroquine shortage.
- West-Ward discontinued hydroxychloroquine tablets in September 2014.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1126>

**Source link:** <http://www.ashp.org>

## Doxycycline Capsules and Tablets

**Apr 06, 2015**

Reason for the Shortage

- Actavis states the reason for the shortage is supply and demand.
- Akorn acquired VersaPharm in August 2014.
- Aqua could not provide a reason for the shortage.
- Teva discontinued their doxycycline presentations in May 2013.
- Major discontinued most doxycycline presentations in February 2013. The company could not provide a reason for the discontinuation.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=977>

**Source link:** <http://www.ashp.org>

## Doxycycline Capsules and Tablets

**Apr 06, 2015**

Reason for the Shortage

- Actavis states the reason for the shortage is supply and demand.

- Akorn acquired VersaPharm in August 2014.
- Aqua could not provide a reason for the shortage.
- Teva discontinued their doxycycline presentations in May 2013.
- Major discontinued most doxycycline presentations in February 2013. The company could not provide a reason for the discontinuation.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=977>

**Source link:** <http://www.ashp.org>

## Doxorubicin Injection

**Apr 06, 2015**

### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired Adriamycin injection from Bedford in July 2014. West-Ward is not actively marketing Adriamycin injection at this time.
- Teva has doxorubicin solution for injection available.
- Fresenius Kabi has doxorubicin solution for injection available.
- Caraco has doxorubicin solution for injection available.
- Pfizer had doxorubicin solution for injection on shortage due to shipping delays.
- Sagent has doxorubicin on shortage due to manufacturing delays.
- Mylan cannot provide a reason for the reason for the doxorubicin solution for injection available.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=464>

**Source link:** <http://www.ashp.org>

## Divalproex Sodium Delayed Release Tablets

**Apr 06, 2015**

### Reason for the Shortage

- Caraco, Teva, Mylan, and Unichem Laboratories cannot provide a reason for the shortage.
- Aurobindo, Dr. Reddy's Laboratories, Lupin, and Qualitest discontinued divalproex sodium delayed release tablets.
- Upsher-Smith had divalproex sodium on long-term back order due to manufacturing delay. Upsher-Smith has transitioned to new NDC numbers.
- Zydus has divalproex sodium delayed-release tablets on allocation due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1124>

**Source link:** <http://www.ashp.org>

## Dibucaine Ointment

**Apr 06, 2015**

### Reason for the Shortage

- Perrigo and Fougera cannot provide a reason for the shortage.
- Geritrex introduced dibucaine 1% ointment in March 2014.
- Novartis divested the rights for all Nupercainal ointment products to Ducere Pharma in 2013.
- These products are available Over-The-Counter.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1074>

**Source link:** <http://www.ashp.org>

## Desmopressin Injection

**Apr 06, 2015**

### Reason for the Shortage

- Teva and Hospira have desmopressin injection on shortage due to manufacturing delays.
- Ferring acquired marketing rights of DDAVP from Sanofi in October 2014.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1010>

**Source link:** <http://www.ashp.org>

## Sterile Empty Vials

**Apr 07, 2015**

### Reason for the Shortage

- Hospira states the shortage is due to increased demand.
- Fresenius Kabi (formerly APP) reduced production of sterile empty vials to permit increased production of drug products affected by critical shortages.
- Sterile empty vials may be available from medical supply distributors.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=890>

**Source link:** <http://www.ashp.org>

## **Nalbuphine Injection**

**Apr 07, 2015**

### Reason for the Shortage

- Hospira has nalbuphine on shortage due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=665>

**Source link:** <http://www.ashp.org>

## **Methylprednisolone Acetate Injection**

**Apr 07, 2015**

### Reason for the Shortage

- Sandoz and Teva could not provide a reason for the shortage.
- Pfizer has Depo-Medrol injection available and is supplying the market.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=923>

**Source link:** <http://www.ashp.org>

## **Ketorolac Tromethamine Injection**

**Apr 07, 2015**

### Reason for the Shortage

- Fresenius Kabi states the shortage was due to manufacturing delays.
- Hospira has ketorolac on shortage due to manufacturing delays for quality improvement activities and increased demand for the product.
- Hospira issued a voluntary recall of several presentations of ketorolac in January 2015 due to potential for particulate matter.
- Sagent states the reason for the shortage is demand exceeding supply.
- West-Ward has ketorolac injection on shortage due to manufacturing delays.
- Ben Venue closed its plant in Bedford, Ohio in July 2014.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.
- Sprix Nasal Spray is not affected by this shortage.



**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=593>

**Source link:** <http://www.ashp.org>

## Cefuroxime Sodium Injection

**Apr 07, 2015**

### Reason for the Shortage

- Sagent states manufacture of cefuroxime 1.5 gram was suspended in March, 2013. No further production is planned.
- Hospira discontinued cefuroxime 1.5 gram and 7.5 gram vials in January, 2013.
- Covis launched the new NDC numbers in August 2013.
- BBraun discontinued their cefuroxime solution in December 2013.
- Fresenius Kabi discontinued manufacturing cefuroxime in 2013.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=990>

**Source link:** <http://www.ashp.org>

## Tacrolimus Capsules

**Apr 08, 2015**

### Reason for the Shortage

- Novartis discontinued all Hecoria presentations in February 2015.
- Mylan discontinued the 500 count presentations in early 2015.
- Mylan and Kremers Urban could not provide a reason for the shortage.
- Sandoz states the reason for the shortage is manufacturing delay.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1149>

**Source link:** <http://www.ashp.org>

## Potassium Chloride Injection

**Apr 08, 2015**

### Reason for the Shortage

- Hospira states the reason for the shortage is manufacturing delays.
- Fresenius Kabi and Baxter could not provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=696>

**Source link:** <http://www.ashp.org>

## Phenazopyridine Hydrochloride

**Apr 08, 2015**

### Reason for the Shortage

- Amneal Pharmaceuticals and SDA Laboratories discontinued phenazopyridine tablets.
- Avkare and Marlex could not provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1144>

**Source link:** <http://www.ashp.org>

## Methylphenidate Hydrochloride Immediate Release Tablets

**Apr 08, 2015**

### Reason for the Shortage

- Mallinckrodt states the shortage was due to delay in obtaining raw materials. The company has stopped using the trade name Methylin and all products are now marketed as methylphenidate immediate-release or extended-release tablets with new NDC numbers.
- Sandoz states that the shortage is due to delay in obtaining raw materials.
- UCB states methylphenidate IR tablets were on shortage due to supply and demand.
- Actavis states the shortage of methylphenidate was due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1167>

**Source link:** <http://www.ashp.org>

## Methylphenidate Hydrochloride Chewable Tablets

**Apr 08, 2015**

### Reason for the Shortage

- Shionogi Pharma has Methylin chewable tablets on shortage due to manufacturing issues.
- Gavis launched methylphenidate chewable tablets in April 2015.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1163>

**Source link:** <http://www.ashp.org>

## Magnesium Sulfate Injection

Apr 08, 2015

### Reason for the Shortage

- American Regent has magnesium sulfate on shortage due to manufacturing delays.
- Fresenius Kabi (formerly APP) has magnesium sulfate injection on shortage due to increased demand for the product.
- Hospira has magnesium sulfate injection on shortage due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=757>

**Source link:** <http://www.ashp.org>

## Indocyanine Green

Apr 08, 2015

### Reason for the Shortage

- Akorn states the reason for the shortage was increased demand.
- Hub Pharmaceuticals states the reason for the shortage was increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1107>

**Source link:** <http://www.ashp.org>

## Hydromorphone Hydrochloride Injection

Apr 08, 2015

### Reason for the Shortage

- Hospira had hydromorphone injection on shortage due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=856>

**Source link:** <http://www.ashp.org>

## Furosemide Injection

Apr 08, 2015

### Reason for the Shortage

- Fresenius Kabi (formerly APP) has furosemide injection on shortage due to increased demand for the product.

- American Regent has furosemide injection on shortage due to manufacturing delays.
- Hospira has furosemide injection available.
- Wockhardt has discontinued all furosemide injection presentations.
- Claris could not provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=636>

**Source link:** <http://www.ashp.org>

## **Daunorubicin Hydrochloride Injection**

**Apr 08, 2015**

Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired daunorubicin injection and Cerubidine injection from Bedford in July 2014. West-Ward is not actively marketing daunorubicin injection or Cerubidine injection at this time.
- Teva's daunorubicin injection has a 12 month shelf-life after manufacturing.
- Teva states daunorubicin was on back order due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1007>

**Source link:** <http://www.ashp.org>

## **Ciprofloxacin Injection**

**Apr 08, 2015**

Reason for the Shortage

- Claris, Sagent, and Sandoz could not provide a reason for the shortage.
- Hospira has ciprofloxacin injection on back order due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=944>

**Source link:** <http://www.ashp.org>

## **Ceftazidime Injection**

**Apr 08, 2015**

Reason for the Shortage

- Hospira had ceftazidime on shortage due to manufacturing delays.
- Sagent has ceftazidime injection on shortage due to increased demand for the product.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=869>

**Source link:** <http://www.ashp.org>

## Carboplatin Solution for Injection

**Apr 08, 2015**

### Reason for the Shortage

- Bedford discontinued carboplatin in May, 2011 to concentrate on the manufacturing of other products.
- Fresenius Kabi has carboplatin on shortage due to increased demand for the product.
- Hospira has carboplatin injection available.
- Mylan Institutional cannot provide a reason for the shortage.
- Sagent has carboplatin injection available.
- Sandoz has carboplatin on shortage due to manufacturing delays.
- Teva had carboplatin injection on allocation due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1005>

**Source link:** <http://www.ashp.org>

## Bupropion Hydrochloride 24 hour ER Tablets

**Apr 08, 2015**

### Reason for the Shortage

- Actavis began transitioning to new NDC numbers in February 2015.
- Par states the reason for the shortage was increased demand for product.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1106>

**Source link:** <http://www.ashp.org>

## Atorvastatin Tablets

**Apr 08, 2015**

### Reason for the Shortage

- In November 2012, Ranbaxy voluntarily recalled 41 lots of atorvastatin tablets due to possible contamination with very small glass particles. Ranbaxy resumed supply of atorvastatin tablets in late-March 2013.
- Ranbaxy discontinued atorvastatin in late-2014.

- Apotex has atorvastatin tablets on allocation due to increased demand.
- Greenstone states the shortage was due to manufacturing delays.
- Major and Sandoz could not provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=989>

**Source link:** <http://www.ashp.org>

## Mesna Injection

**Apr 09, 2015**

### Reason for the Shortage

- Fresenius Kabi had mesna on shortage due to increased demand.
- Mylan cannot give a reason for the shortage of mesna.
- Sagent has mesna on shortage due to manufacturing delays.
- Teva had a shortage of mesna injection due to manufacturing delays.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired mesna injection from Bedford in July 2014. West-Ward is not actively marketing mesna injection at this time.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1148>

**Source link:** <http://www.ashp.org>

## Lidocaine Hydrochloride and 5% Dextrose injection

**Apr 09, 2015**

### Reason for the Shortage

- Baxter and Hospira have lidocaine premixed injection on shortage due to manufacturing delays and increased demand.
- BBraun has lidocaine and dextrose premixed bags on shortage due to increased demand for the product.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1177>

**Source link:** <http://www.ashp.org>

## Lidocaine Injection

Apr 09, 2015

### Reason for the Shortage

- Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
- AuroMedics introduced lidocaine injection in February 2014.
- Fresenius Kabi has Xylocaine and lidocaine presentations on shortage due to increased demand for the product.
- Hospira has lidocaine presentations on shortage due to manufacturing delays and increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=859>

**Source link:** <http://www.ashp.org>

## Chorionic Gonadotropin (Human) Injection

Apr 10, 2015

### Reason for the Shortage

- Merck states their product is on allocation to prevent use in the gray market.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=382>

**Source link:** <http://www.ashp.org>

## Azithromycin Injection

Apr 10, 2015

### Reason for the Shortage

- Fresenius Kabi has azithromycin on shortage due to increased demand.
- Hospira has azithromycin injection on shortage due to manufacturing delays.
- Sagent had azithromycin injection on shortage due to manufacturing delays.
- Pfizer had Zithromax injection on shortage due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=936>

**Source link:** <http://www.ashp.org>

## Acetylcysteine Inhalation Solution

Apr 10, 2015

### Reason for the Shortage

- American Regent has acetylcysteine inhalation on shortage due to manufacturing delays.
- Roxane Labs discontinued acetylcysteine inhalation solution in April 2014.
- Hospira had acetylcysteine inhalation solution on shortage due to manufacturing delay.
- Fresenius Kabi states the reason for the shortage was increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=932>

**Source link:** <http://www.ashp.org>

## Vitamin E Aqueous Oral Solution

Apr 13, 2015

### Reason for the Shortage

- Hospira is changing manufacturing sites from a 3rd party manufacturer to in-house manufacturing. This has caused a delay in production.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=965>

**Source link:** <http://www.ashp.org>

## Trace Elements Injection

Apr 13, 2015

### Reason for the Shortage

- American Regent has trace element injection on back order due to manufacturing delays.
- American Regent is the sole supplier of FDA-approved combined trace elements.
- In cooperation with FDA, Fresenius Kabi USA is providing Addamel N (adult trace element injection) and Peditrace (pediatric trace element injection) to the US market to help alleviate the shortage. Addamel N and Peditrace are manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG, the parent company of Fresenius Kabi, USA.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=785>

**Source link:** <http://www.ashp.org>



## Esomeprazole Injection

Apr 13, 2015

### Reason for the Shortage

- Sun Pharmaceuticals states the reason for shortage is manufacturing delay.
- Astra Zeneca has Nexium IV on shortage due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1175>

**Source link:** <http://www.ashp.org>

## Diphtheria, Tetanus Toxoid, and Acellular Pertussis Vaccine (DTaP)

Apr 13, 2015

### Reason for the Shortage

- Sanofi Pasteur states the reason for the Daptacel shortage is manufacturing delay.<sup>1,2,3</sup>
- Sanofi Pasteur discontinued Tripedia in 2011.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=922>

**Source link:** <http://www.ashp.org>

## Diphtheria, Tetanus Toxoid, and Acellular Pertussis and Inactivated Poliovirus and Haemophilus B Conjugate Vaccine (DTaP - IPV/Hib)

Apr 13, 2015

### Reason for the Shortage

- Sanofi Pasteur states the reason for the shortage is manufacturing delay, which will reduce supplies below current demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=921>

**Source link:** <http://www.ashp.org>

## Buprenorphine Sublingual Tablets

Apr 13, 2015

### Reason for the Shortage

- Teva could not provide a reason for the shortage.

- Akorn acquired Hi-Tech Pharmacal in 2014.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1030>

**Source link:** <http://www.ashp.org>

## **Black Widow Antivenin (Latrodectus Mactans)**

**Apr 13, 2015**

Reason for the Shortage

- Merck has low inventory of Antivenin Latrodectus Mactans.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=670>

**Source link:** <http://www.ashp.org>

## **Polymyxin B Sulfate Injection**

**Apr 14, 2015**

Reason for the Shortage

- Fresenius Kabi could not provide a reason for the shortage.
- Sagent suspended manufacturing of Polymyxin B sulfate injection in October, 2012.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including polymyxin B sulfate injection. West-Ward is not actively marketing polymyxin B sulfate injection.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=974>

**Source link:** <http://www.ashp.org>

## **Rocuronium Injection**

**Apr 15, 2015**

Reason for the Shortage

- Merck discontinued Zemuron 10 mL multidose vials in the 3rd Quarter of 2013. Merck discontinued Zemuron 5 mL vials in June 2014.
- Mylan Institutional states the reason for the shortage is increased demand.
- Hospira has rocuronium on shortage due to manufacturing delays.
- Teva has rocuronium on shortage due to manufacturing delays.
- Fresenius Kabi and Sagent cited increased demand as the reason for this shortage.

- Sandoz cannot provide a reason for the shortage.
- The Medicines Company launched rocuronium in early 2014.
- X-Gen has rocuronium injection available.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=434>

**Source link:** <http://www.ashp.org>

## Metoprolol Injection

**Apr 15, 2015**

### Reason for the Shortage

- American Regent has metoprolol injection on shortage due to manufacturing delays.
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Claris cannot provide a reason for the shortage.
- Fresenius Kabi states the shortage is due to increased demand for the product.
- Hospira states the shortage is due to increased demand for the product.
- Novartis has Lopressor injection available.
- Sagent states the shortage is due to increased demand for the product.
- Sandoz cannot provide a reason for the shortage.
- West-Ward has metoprolol injection available.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=813>

**Source link:** <http://www.ashp.org>

## Methotrexate Injection

**Apr 15, 2015**

### Reason for the Shortage

- Mylan Institutional cannot provide a reason for the shortage.
- Sandoz states the reason for the shortage is manufacturing delay.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including methotrexate injection. West-Ward is not actively marketing methotrexate injection.

**Article Link:** <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=26>

**Source link:** <http://www.ashp.org>

## Mercaptopurine Tablets

Apr 15, 2015

### Reason for the Shortage

- Par discontinued mercaptopurine tablets in October 2014.
- Teva could not provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=997>

**Source link:** <http://www.ashp.org>

## Lorazepam injectable presentations

Apr 15, 2015

### Reason for the Shortage

- Bedford discontinued lorazepam in May, 2011 to concentrate on the manufacturing of other products.
- West-Ward acquired Baxter's lorazepam injection products in May, 2011. NDC numbers for the lorazepam and Ativan products were changed in April, 2012.
- West-Ward had Ativan on back order due to increase surplus of the lorazepam presentations.
- Hospira states lorazepam vials are on shortage due to increased demand and manufacturing delays. The 1 mL iSecure syringes were discontinued in September 2011.
- Akorn increased production to help meet demand.
- Amphastar had lorazepam 2 mg/mL vials on shortage due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=747>

**Source link:** <http://www.ashp.org>

## Lidocaine with Epinephrine Injection

Apr 15, 2015

### Reason for the Shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product.
- Hospira has lidocaine with epinephrine presentations on shortage due to manufacturing delays and increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=860>

**Source link:** <http://www.ashp.org>

## Epinephrine Injection

**Apr 15, 2015**

### Reason for the Shortage

- American Regent discontinued both epinephrine presentations in early-2015.
- Amphastar states the shortage is due to increased demand.
- BPI Labs received FDA approval for epinephrine injection in 2014 and the company launched product in February 2015.
- Hospira has epinephrine syringes on shortage due to manufacturing delays.

**Article Link:** <http://www.ashp.org/menu/DrugShortages/CurrentShortages?sort=2>

**Source link:** <http://www.ashp.org>

## Ciprofloxacin Immediate-Release Tablets

**Apr 15, 2015**

### Reason for the Shortage

- Ranbaxy has an FDA import ban on several of their products manufactured in India.
- Carlsbad Technology discontinued ciprofloxacin tablets in 2014.
- Marlex is unable to provide a reason for their shortage.
- Major discontinued their ciprofloxacin immediate-release tablets in February, 2010.
- Teva discontinued their ciprofloxacin immediate-release tablet, unit dose presentations in June, 2010.
- Schering has discontinued all Cipro immediate-release tablet presentations.
- UDL has discontinued all ciprofloxacin immediate-release 250 mg unit-dose tablets.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=572>

**Source link:** <http://www.ashp.org>

## Calcium Acetate Capsules

**Apr 15, 2015**

### Reason for the Shortage

- Fresenius Medical cannot provide a reason for the shortage.
- Hawthorne states the reason for the shortage was manufacturing delay.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1002>

**Source link:** <http://www.ashp.org>

## **Bupivacaine with epinephrine Injection**

**Apr 15, 2015**

### Reason for the Shortage

- Fresenius Kabi has Sensorcaine with epinephrine on shortage due to increased demand for the product.
- Hospira had bupivacaine with epinephrine on shortage due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=937>

**Source link:** <http://www.ashp.org>

## **Atenolol Tablets**

**Apr 15, 2015**

### Reason for the Shortage

- AstraZeneca divested Tenormin to Almatica in January 2015.
- Avkare and Mylan Pharmaceuticals could not provide a reason for the shortage.
- Pack Pharmaceuticals discontinued atenolol tablets in October 2014.
- Ranbaxy has atenolol tablets on shortage due to manufacturing delays.
- Zydus has atenolol tablets on allocation due to increased demand.
- Aurobindo and Caraco have discontinued atenolol tablets.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1127>

**Source link:** <http://www.ashp.org>

## **Amoxicillin 875 mg Tablets**

**Apr 15, 2015**

### Reason for the Shortage

- Aurobindo had amoxicillin on shortage due to manufacturing delays.
- Dr Reddy's discontinued amoxicillin 875 mg tablets in June 2014.
- Ranbaxy has an FDA import ban on amoxicillin tablets.
- Sandoz cannot provide a reason for the shortage.
- West-Ward has amoxicillin on allocation due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1141>

**Source link:** <http://www.ashp.org>

## Sodium Phosphate Injection

**Apr 16, 2015**

### Reason for the Shortage

- American Regent has sodium phosphate injection on back order due to manufacturing delays.
- American Regent has issued a statement that all lots of sodium phosphate have potential for crystallization. Do not use if any particles are present.
- Hospira had sodium phosphate injection on shortage due to manufacturing delays.
- In cooperation with FDA, Fresenius Kabi USA is providing Glycophos (sodium glycerophosphate) injection to the US market to help alleviate the shortage. Glycophos is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG.
- Fresenius Kabi launched sodium phosphate injection in mid-January 2014.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=770>

**Source link:** <http://www.ashp.org>

## Piperacillin Tazobactam Injection

**Apr 16, 2015**

### Reason for the Shortage

- Apotex has piperacillin/tazobactam on shortage due to regulatory delays.
- AuroMedics and Sandoz could not provide a reason for the shortage.
- Baxter has Zosyn frozen premixes on allocation due to increased demand.
- Fresenius Kabi has piperacillin/tazobactam on shortage due to increased demand.
- Hospira has piperacillin/tazobactam on shortage due to manufacturing delays.
- Sagent has piperacillin/tazobactam on shortage due to increased demand.
- Pfizer has Zosyn on shortage due to manufacturing delays. Pfizer estimates there will be supply shortages through September 2015 for the single dose vials and 1st quarter 2017 for the bulk vials.
- WG Critical Care states the reason for the shortage is increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1075>

**Source link:** <http://www.ashp.org>

## Milrinone Injection

Apr 16, 2015

### Reason for the Shortage

- Fresenius Kabi states the reason for the shortage is increased demand for the product.
- West-Ward states the shortage is due to manufacturing delays.
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Apotex, Bioniche, and Teva discontinued milrinone 1 mg/mL vials.
- Sanofi-Aventis discontinued Primacor injection.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=741>

**Source link:** <http://www.ashp.org>

## Dextran Low Molecular Weight (Dextran 40), 10% Injection

Apr 16, 2015

### Reason for the Shortage

- Hospira states the reason for the shortage is manufacturing delay.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1108>

**Source link:** <http://www.ashp.org>

## Dexamethasone Sodium Phosphate

Apr 16, 2015

### Reason for the Shortage

- American Regent has dexamethasone sodium phosphate on shortage due to manufacturing delays.
- Fresenius Kabi states the dexamethasone sodium phosphate shortage is due to supply and demand issues.
- Baxter could not provide a reason for the shortage. Baxter sold several products to West-Ward in mid-2011.
- West-Ward had dexamethasone sodium phosphate injection on shortage due to increased demand.
- Pfizer divested all dexamethasone presentation to Mylan Institutional on December 6, 2013.
- Mylan Institutional states the shortage is due to increased demand.



**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=751>

**Source link:** <http://www.ashp.org>

## Cardioplegic Solution for Cardiac Perfusion

**Apr 16, 2015**

### Reason for the Shortage

- Baxter states the reason for the shortage is increased demand.
- Hospira states the reason for the shortage is manufacturing delay.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1172>

**Source link:** <http://www.ashp.org>

## Calcium Gluconate Injection

**Apr 16, 2015**

### Reason for the Shortage

- American Regent has calcium gluconate on shortage due to manufacturing delays.
- Fresenius Kabi has replaced calcium gluconate glass vials with plastic vials.
- American Regent has issued a statement that all lots of calcium gluconate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product.

**Article Link:** <http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=48>

**Source link:** <http://www.ashp.org>

## Calcium Chloride Injection

**Apr 16, 2015**

### Reason for the Shortage

- American Regent has calcium chloride on shortage due to manufacturing delays.
- Amphastar had calcium chloride on shortage due to increased demand.
- Hospira has calcium chloride on shortage due to manufacturing delays.
- Mylan Institutional cannot provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=941>

**Source link:** <http://www.ashp.org>

## Caffeine Citrate Injection and Oral Solution

Apr 16, 2015

### Reason for the Shortage

- American Regent has caffeine citrate on shortage due to manufacturing delays.
- Caraco cannot provide a reason for the shortage.
- Paddock discontinued caffeine citrate injection and oral solution in May 2014.
- Sagent states the reason for the shortage is manufacturing delays.
- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired Cafcit from Bedford in July 2014. West-Ward is actively marketing Cafcit injection.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=862>

**Source link:** <http://www.ashp.org>

## Bupivacaine Injection

Apr 16, 2015

### Reason for the Shortage

- Fresenius Kabi (formerly APP) has Sensorcaine on shortage due to increased demand for the product.
- Hospira has bupivacaine on shortage due to manufacturing delays.
- AuroMedics introduced bupivacaine injection in February 2014.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=864>

**Source link:** <http://www.ashp.org>

## Ampicillin Sulbactam

Apr 16, 2015

### Reason for the Shortage

- AuroMedics Pharma launched new product in mid-June, 2012.
- Hospira states that ampicillin sulbactam vials are on back order due to manufacturing delay.
- Mylan Institutional discontinued ampicillin sulbactam injection in late 2013.
- Sagent has ampicillin sulbactam vials on allocation due to increased demand for the product.
- WG Critical Care states the shortage is due to increased demand.
- Pfizer and Sandoz cannot provide a reason for the shortage.
- WG Critical Care launched ampicillin sulbactam 1.5 gram vials in March 2014.

- West-Ward acquired several Baxter products in early 2011.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=805>

**Source link:** <http://www.ashp.org>

## Amino Acid Products

**Apr 16, 2015**

### Reason for the Shortage

- Baxter is unable to provide a reason for the shortage.
- BBraun has Plenamine and TrophAmine on allocation due to increased demand.
- Hospira has amino acid products on back order due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=671>

**Source link:** <http://www.ashp.org>

## Adenosine Injection

**Apr 16, 2015**

### Reason for the Shortage

- Astellas had Adenoscan on back order due to increased demand. This back order is now resolved. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Sagent has adenosine vials on shortage due to increased demand.
- Teva has discontinued their adenosine injection.
- West-Ward could not provide a reason for the shortage.
- Wockhardt discontinued their adenosine 3 mg/mL 2 mL and 4 mL syringes.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=976>

**Source link:** <http://www.ashp.org>

## Vancomycin Hydrochloride Injection

**Apr 16, 2015**

### Reason for the Shortage

- Hospira has vancomycin on shortage due to increased demand.

- Fresenius Kabi has vancomycin injection on shortage due to increased demand.
- Mylan Institutional cannot provide a reason for the shortage.
- Baxter is allocating vancomycin.
- Sagent has vancomycin injection on allocation due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=132>

**Source link:** <http://www.ashp.org>

## Ondansetron Injection

**Apr 17, 2015**

### Reason for the Shortage

- AuroMedics did not provide a reason for the shortage.
- Caraco temporarily discontinued ondansetron injection.
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July, 2014.
- Heritage cannot provide a reason for the shortage.
- Mylan Institutional has new NDC numbers for ondansetron 2 mg/mL injectable products.
- Sagent has ondansetron on back order due to increased demand.
- Teva re-launched ondansetron 20 mL injection in 2015.
- West-Ward had ondansetron on back order due to increased demand.
- Wockhardt has ondansetron injection on an FDA import alert.
- All presentations of ondansetron 32 mg/50 mL premixed bags have been discontinued.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1040>

**Source link:** <http://www.ashp.org>

## Nafcillin Sodium

**Apr 17, 2015**

### Reason for the Shortage

- AuroMedics and Fresenius Kabi state the reason for the shortage is increased demand.
- Sagent stated the reason for the shortage is increased demand.
- Sandoz states the reason for the shortage is internal issues.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1136>

**Source link:** <http://www.ashp.org>

## Etomidate Injection

Apr 17, 2015

### Reason for the Shortage

- American Regent has etomidate injection on shortage due to manufacturing delays.
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Hospira has Amidate injection on shortage due to manufacturing delays.
- Mylan Institutional acquired etomidate injection from Pfizer on December 6, 2013. Mylan Institutional divested some presentations of etomidate injection to JHP Pharmaceuticals in April 2014.
- Mylan recalled 10 lots of etomidate injection with the Pfizer label in February 2014. The recall was due to the presence of particulate matter and missing lot numbers and expiration dates on the vials.
- Par Pharmaceuticals acquired JHP Pharmaceuticals in early 2014. Par Sterile Products discontinued etomidate in early 2015.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=419>

**Source link:** <http://www.ashp.org>

## Clindamycin Injection

Apr 17, 2015

### Reason for the Shortage

- Pfizer states the Cleocin Add-Vantage vials are on shortage due to manufacturing delays.
- Hospira has clindamycin injection on shortage due to manufacturing delays.
- Akorn launched clindamycin injection in June 2013.
- Sandoz had clindamycin injection on shortage due to increased demand.
- Sagent has clindamycin injection on shortage due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1029>

**Source link:** <http://www.ashp.org>

## Cefepime Injection

Apr 17, 2015

### Reason for the Shortage

- Apotex could not provide a reason for the shortage.
- Fresenius Kabi has cefepime injection on shortage due to manufacturing delays.
- Sagent has cefepime injection on shortage due to increased demand.

- Sandoz cannot provide a reason for the shortage.
- Hospira has Maxipime on shortage due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1176>

**Source link:** <http://www.ashp.org>

## Cefazolin Injection

**Apr 17, 2015**

### Reason for the Shortage

- Fresenius Kabi, BBraun, West-Ward, and WG Critical Care have cefazolin on shortage due to increased demand.
- WG Critical Care is not producing cefazolin 20 gram to focus on other strengths.
- Apotex and Sandoz have cefazolin on shortage due to manufacturing delays.
- Hospira has cefazolin on shortage due to manufacturing delays.
- Sagent has cefazolin on shortage due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=987>

**Source link:** <http://www.ashp.org>

## Amikacin Injection

**Apr 17, 2015**

### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired amikacin injection from Bedford in July 2014. West-Ward is not actively marketing amikacin 250 mg/mL 4 mL vials at this time.
- Teva's product was unavailable due to manufacturing delays.
- Heritage cannot provide a reason for the shortage. However, amikacin injection is manufactured by Emcure for Heritage. An Emcure manufacturing site was recently noted to have FDA observations related to GMP and aseptic practices.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=501>

**Source link:** <http://www.ashp.org>

## Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

Apr 20, 2015

### Reason for the Shortage

- Sanofi-Pasteur had Adacel is in short supply due to manufacturing delays. This product is also known as adult tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine.
- Sanofi-Pasteur updated the NDC numbers on the individual vials and syringes (unit of use). The NDC numbers on the outside cartons (unit of sale) remain the same.
- GlaxoSmithKline has available Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Boostrix). The 1 count Boostrix syringe is no longer made.
- GlaxoSmithKline has Boostrix on shortage due to increased demand.
- Adult Tetanus and Diphtheria Toxoids Adsorbed (Td) (Tenivac, Sanofi-Pasteur) is not affected by this shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1051>

**Source link:** <http://www.ashp.org>

## Testosterone Cypionate Intramuscular Injection

Apr 20, 2015

### Reason for the Shortage

- Actavis discontinued testosterone cypionate injection in 2015.
- Paddock has testosterone on shortage due to increased demand and shipping delays from their contract manufacturer.
- West-Ward had testosterone cypionate on shortage due to manufacturing delays.
- Sandoz discontinued testosterone cypionate 200 mg/mL 1 mL and 10 mL vials in September 2011. Sandoz discontinued final presentation in first half of 2012.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=638>

**Source link:** <http://www.ashp.org>

## Synthetic Conjugated Estrogen

Apr 20, 2015

### Reason for the Shortage

- Teva discontinued Cenestin in late-August 2014.
- Premarin is not affected by this shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1087>

**Source link:** <http://www.ashp.org>

## Sodium Chloride 0.9% Injection Bags

**Apr 20, 2015**

### Reason for the Shortage

- Baxter has 0.9% sodium chloride on shortage due to increased demand.
- BBraun had 0.9% sodium chloride on allocation due to increased demand.
- Hospira cites increased demand as the reason for the shortage.
- In cooperation with the FDA, Fresenius Kabi is providing 0.9% sodium chloride to the US market to help alleviate the national shortage. This 0.9% sodium chloride is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG. There will be presentations available with Australian/English label and the package insert is the same for all imported presentations.
- In cooperation with the FDA, Baxter is providing imported 0.9% sodium chloride to the US market to help alleviate the national shortage. This 0.9% sodium chloride in Viaflo containers is manufactured in Spain by Baxter.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=993>

**Source link:** <http://www.ashp.org>

## Sodium Chloride 0.45% Injection Bags

**Apr 20, 2015**

### Reason for the Shortage

- Baxter had 0.45% sodium chloride on shortage due to increased demand.
- BBraun had 0.45% sodium chloride on allocation due to increased demand.
- Hospira cited increased demand as the reason for the shortage.

**ArticleLink:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1083>

**Source link:** <http://www.ashp.org>



## Sodium Bicarbonate Injection

Apr 20, 2015

### Reason for the Shortage

- Hospira has sodium bicarbonate on back order due to increased demand.
- Amphastar had sodium bicarbonate on back order due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=788>

**Source link:** <http://www.ashp.org>

## Posaconazole Oral Suspension

Apr 20, 2015

### Reason for the Shortage

- Merck states the shortage is due to manufacturing delays.
- Noxafil delayed-release tablets and intravenous injections are not affected by this shortage.
- Merck is the only supplier of posaconazole oral suspension.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=695>

**Source link:** <http://www.ashp.org>

## Oxytocin Injection

Apr 20, 2015

### Reason for the Shortage

- Fresenius Kabi states the shortage is due to increased demand.
- Par Sterile Products (formerly JHP) discontinued generic oxytocin injection in July 2014.
- West-Ward cannot provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=876>

**Source link:** <http://www.ashp.org>

## Memantine Hydrochloride

Apr 20, 2015

### Reason for the Shortage

- Forest states the reason for the shortage of Namenda XR capsules is manufacturing delay.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1082>

**Source link:** <http://www.ashp.org>

## Dextrose 5% Injection Large Volume Bags

Apr 20, 2015

### Reason for the Shortage

- Baxter states the shortage is due to increased demand.
- BBraun had 5% dextrose on allocation due to increased demand.
- Hospira states the shortage is due to increased demand and manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1081>

**Source link:** <http://www.ashp.org>

## Cisatracurium Injection

Apr 20, 2015

### Reason for the Shortage

- Sandoz could not provide a reason for the shortage.
- Nimbex injection was on shortage due to increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1072>

**Source link:** <http://www.ashp.org>

## Ceftriaxone Sodium Injection

Apr 20, 2015

### Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Fresenius Kabi states the reason for the shortage is increased demand.

- Hospira states the reason for the shortage is manufacturing delay.
- Sagent states the reason for the shortage is increased demand.
- Sandoz could not provide a reason for the shortage.
- WG Critical Care states the reason for the shortage is increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1101>

**Source link:** <http://www.ashp.org>

## Atropine Sulfate Ophthalmic Solution

**Apr 20, 2015**

### Reason for the Shortage

- Akorn received FDA approval for atropine sulfate 1% ophthalmic solution in July 2014; this new product launched in January 2015. All other atropine sulfate ophthalmic solution products are unapproved products.
- Sandoz could not provide a reason for the shortage.
- Valeant discontinued their atropine sulfate 1% ophthalmic solution products in 2015.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1146>

**Source link:** <http://www.ashp.org>

## Phenylephrine 2.5% and 10% Ophthalmic Solution

**Apr 21, 2015**

### Reason for the Shortage

- Akorn received FDA approval of phenylephrine ophthalmic solution in January 2015 and has product available.
- Alcon discontinued phenylephrine 2.5% ophthalmic solution with the Sandoz label in April 2014.
- Alcon discontinued Mydrin 2.5% ophthalmic solution in 2014.
- Hub discontinued phenylephrine 2.5% and 10% ophthalmic solution in 2013.
- Phenylephrine 2.5% and 10% from Paragon BioTeck was the first FDA-approved phenylephrine ophthalmic product. Paragon BioTeck supplies phenylephrine ophthalmic solution 2.5% and 10% and this is distributed by Bausch & Lomb (a division of Valeant).

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1105>

**Source link:** <http://www.ashp.org>

## Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%

Apr 21, 2015

### Reason for the Shortage

- Akorn could not provide a reason for the shortage.
- Roxane states the shortage was due to increased demand.
- Qualitest will not provide shortage information for any of their products because they consider the information to be proprietary.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1171>

**Source link:** <http://www.ashp.org>

## Chloroquine Tablets

Apr 21, 2015

### Reason for the Shortage

- Global Pharmaceuticals discontinued chloroquine tablets in 2014.
- Rising discontinued chloroquine tablets in February 2015.
- Ranbaxy has chloroquine tablets on shortage due to third party supply issues.
- West-Ward cannot provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1178>

**Source link:** <http://www.ashp.org>

## Benzonatate Capsules

Apr 22, 2015

### Reason for the Shortage

- Amneal and Ascend Laboratories cannot provide a reason for the shortage.
- Caraco will discontinue benzonatate capsules when current supplies are depleted.
- Zydus states the reason for the shortage is manufacturing delay.
- Pfizer has Tessalon Perles on shortage due to supply and demand issues.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1155>

**Source link:** <http://www.ashp.org>

## Acetaminophen and Codeine Phosphate 300 mg/30 mg Tablets

Apr 22, 2015

### Reason for the Shortage

- Mallinckrodt states the shortage is due a variety of market conditions.
- Amneal, Aurobindo, Mylan, and Teva could not provide a reason for the shortage.
- Qualitest will not provide shortage information for any of their products because they consider the information to be proprietary.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1152>

**Source link:** <http://www.ashp.org>

## Leflunomide Tablets

April 24, 2015

### Reason for the Shortage

- Apotex states the shortage is due to a delay in obtaining active ingredient.
- Heritage states the shortage is due to a delay in obtaining active ingredient.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=711>

**Source Link:** <http://www.ashp.org>

## Sumatriptan Succinate Injection

April 27, 2015

### Reason for the Shortage

- Sagent states the reason for the shortage is increased demand.
- GlaxoSmithKline could not provide a reason for the shortage.
- Pfizer has had Alsuma on shortage since September 2013 due to manufacturing issues.
- Zogenix sold Sumavel DosePro to Endo in 2014.
- Teva has temporarily suspended the production of sumatriptan injection.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1085>

**Source Link:** <http://www.ashp.org>

## Reserpine Oral Tablets

April 27, 2015

### Reason for the Shortage

- Sandoz said the shortage is due to a delay in obtaining raw materials.
- There are no other manufacturers of reserpine tablets.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=975>

**Source Link:** <http://www.ashp.org>

## Prochlorperazine Edisylate Injection

April 27, 2015

### Reason for the Shortage

- Heritage Pharmaceuticals could not provide a reason for the shortage

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1063>

**Source Link:** <http://www.ashp.org>

## Nitroglycerin Injection

April 27, 2015

### Reason for the Shortage

- American Regent had nitroglycerin vials on back order due to manufacturing delays.
- Hospira discontinued nitroglycerin injection in early 2015.
- Baxter had nitroglycerin premixes on shortage due to a raw material supply issue.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=786>

**Source Link:** <http://www.ashp.org>

## L-Cysteine Hydrochloride Injection

April 27, 2015

### Reason for the Shortage

- American Regent has L-cysteine hydrochloride injection on back order due to manufacturing delays.
- Sandoz cannot provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=632>

**Source Link:** <http://www.ashp.org>

## **Fomepizole Injection**

**April 27, 2015**

Reason for the Shortage

- Sandoz could not provide a reason for the shortage. However, fomepizole injection is manufactured by Emcure for Sandoz. An Emcure manufacturing site was recently noted to have FDA observations related to GMP and aseptic practices.
- X-Gen could not provide a reason for the shortage.
- Mylan Institutional could not provide a reason for the shortage.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1173>

**Source Link:** <http://www.ashp.org>

## **Disopyramide Phosphate Controlled-release Capsules**

**April 27, 2015**

Reason for the Shortage

- Pfizer has Norpace CR on shortage due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1139>

**Source Link:** <http://www.ashp.org>

## **Dextrose (50%) Injection**

**April 27, 2015**

Reason for the Shortage

- Hospira states the shortage is due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1012>

**Source Link:** <http://www.ashp.org>

## Ceftazidime Injection

April 27, 2015

### Reason for the Shortage

- Covis has Fortaz premixed bags on shortage due to increased demand.
- Hospira had ceftazidime on shortage due to manufacturing delays.
- Sagent has ceftazidime injection on shortage due to increased demand for the product.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=869>

**Source Link:** <http://www.ashp.org>

## BCG Vaccine Live Intravesical

April 27, 2015

### Reason for the Shortage

- Sanofi Pasteur states the reason for the shortage is manufacturing delay.
- Merck states the reason for the shortage is manufacturing delay.
- Merck states Tice BCG vaccine percutaneous for tuberculosis (Merck, NDC 00052-0603-02) is also affected because this product is manufactured at the same facility.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=915>

**Source Link:** <http://www.ashp.org>

## Azathioprine Tablets

April 27, 2015

### Reason for the Shortage

- Roxane discontinued azathioprine tablets in mid-January 2015 due to problems obtaining active ingredient.
- Salix and Zydus cannot provide a reason for the shortage.
- Prometheus Laboratories states the reason for the shortage was increased demand.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1123>

**Source Link:** <http://www.ashp.org>



## Atorvastatin Tablets

April 27, 2015

### Reason for the Shortage

- In November 2012, Ranbaxy voluntarily recalled 41 lots of atorvastatin tablets due to possible contamination with very small glass particles. Ranbaxy resumed supply of atorvastatin tablets in late-March 2013.
- Ranbaxy discontinued atorvastatin in late-2014.
- Apotex has atorvastatin tablets on allocation due to increased demand.
- Greenstone states the shortage was due to manufacturing delays.
- Major and Sandoz could not provide a reason for the shortage.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=989>

**Source Link:** <http://www.ashp.org>

## Atenolol Tablets

April 27, 2015

### Reason for the Shortage

- AstraZeneca divested Tenormin to Almatica in January 2015.
- Avkare and Mylan Pharmaceuticals could not provide a reason for the shortage.
- Pack Pharmaceuticals discontinued atenolol tablets in October 2014.
- Ranbaxy has atenolol tablets on shortage due to manufacturing delays.
- Zydus has atenolol tablets on allocation due to increased demand.
- Aurobindo and Caraco have discontinued atenolol tablets.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1127>

**Source Link:** <http://www.ashp.org>

## Amino Acid Products

April 27, 2015

### Reason for the Shortage

- Baxter is unable to provide a reason for the shortage.
- BBraun has Plenamine and TrophAmine on allocation due to increased demand.
- Hospira has amino acid products on back order due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=671>

**Source Link:** <http://www.ashp.org>

## Amikacin Injection

**April 27, 2015**

### Reason for the Shortage

- West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired amikacin injection from Bedford in July 2014. West-Ward is not actively marketing amikacin 250 mg/mL 4 mL vials at this time.
- Teva's product was unavailable due to manufacturing delays.
- Heritage has amikacin injection on shortage due to manufacturing delays.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=501>

**Source Link:** <http://www.ashp.org>

## Adenosine Injection

**April 27, 2015**

### Reason for the Shortage

- Astellas discontinued Adenoscan in April 2015. Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.
- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Sagent has adenosine vials on shortage due to increased demand..
- Teva has discontinued their adenosine injection.
- West-Ward could not provide a reason for the shortage.
- Wockhardt discontinued their adenosine 3 mg/mL 2 mL and 4 mL syringes.

### **Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=976>

**Source Link:** <http://www.ashp.org>

## Zinc Injection

**April 28, 2015**

### Reason for the Shortage

- Hospira states the shortage of zinc chloride injection was due to manufacturing delays.

- American Regent states the shortage of zinc sulfate injection is due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=777>

**Source Link:** <http://www.ashp.org>

## Vancomycin Hydrochloride Injection

**April 28, 2015**

Reason for the Shortage

- Hospira has vancomycin on shortage due to increased demand.
- Fresenius Kabi has vancomycin injection on shortage due to increased demand.
- Mylan Institutional cannot provide a reason for the shortage.
- Baxter is allocating vancomycin.
- Sagent has vancomycin injection on allocation due to increased demand.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=132>

**Source Link:** <http://www.ashp.org>

## Etomidate Injection

**April 28, 2015**

Reason for the Shortage

- American Regent has etomidate injection on shortage due to manufacturing delays.
- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Hospira has Amidate injection on shortage due to increased demand.
- Par Sterile Products discontinued etomidate in early 2015.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=419>

**Source Link:** <http://www.ashp.org>

## Dimercaprol Injection

**April 28, 2015**

Reason for the Shortage

- Akorn states BAL in Oil is on shortage due to manufacturing delays.

**Article Link:**

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1086>

**Source Link:** <http://www.ashp.org>

\* Please refer to ASHP website for more information

## NEW DRUGS COMING TO MARKET

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
LY2963016	Boehringer Ingelheim/Eli Lilly	INJ (SC)	Type I and II diabetes	Novel version of insulin glargine (biosimilar to Lantus)	NDA was filed 12-2013 under 505(b)(2) application; received tentative approval 8/2014; patent infringement lawsuit may delay launch beyond 2/2015
Veruprevir (ABT-450)/ Ombitasvir (ABT-267)/ Dasabuvir (ABT-333)	AbbVie	PO	Hepatitis C	Hepatitis C virus NS3/4A protease inhibitor (given with ritonavir as booster)/NS5A inhibitor combination given with NS5B polymerase inhibitor dasabuvir	All oral triple therapy receives FDA breakthrough therapy designation 5/2013; NDA filed 4/22/2014; FDA action expected 12/2014
Sonidegib (LDE-225)	Novartis	PO	Basal cell carcinoma	Smoothend (Smo) antagonist; Hedgehog (Hh) signaling pathway inhibitor	NDA filed 10/2014
Evolocumab (AMG-145)	Amgen	INJ (SC)	Hypercholesterolemia	Fully human antibody that targets PCSK9; dosed every 2 or every 4 weeks in studies	NDA filed 8/2014; FDA action date 8/2015
Brexipiprazole	Otsuka	PO	Depression, ADHD, schizophrenia	D2 dopamine partial agonist	NDA filed 7/2014; FDA action date 7/2015
Aripiprazole lauroxil	Alkermes	INJ	Schizophrenia	Long-acting atypical antipsychotic dosed every 2	NDA filed 8/2014; FDA action date 8/2015

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
				months	
Eluxadoline (JNJ-27018966)	Janssen/ Furiex	PO	Irritable bowel syndrome	Opioid delta receptor antagonists; opioid mu receptor agonists	NDA filed 9/2014; FDA priority review
Rolapitant	TESARO/ OPKO Health	PO	Chemotherapy induced nausea and vomiting (prevention)	Neurokinin 1 receptor antagonists	NDA filed 9/2014
Drisapersen	Prosensa	INJ (SC)	Duchenne Muscular Dystrophy	Antisense nucleotide that induced specific skipping of exon 51 during splicing	Phase III; FDA breakthrough therapy designation granted 6/2013; Rolling NDA initiated 10/2014
Olodaterol/tiotropium	Boehringer Ingelheim	INH	COPD	Fixed-dose LABA/LAMA combination with Respimat inhaler	NDA filed 8/2014
Mepolizumab (Bosatria)	GSK	INJ (IV,SC)	Asthma, nasal polyposis	Humanized monoclonal antibody against human interleukin-5 (IL-5)	BLA filed 11/2014 for treatment of asthma
Ivacaftor/lumacaftor	Vertex	PO	Cystic fibrosis	Fixed-dose combination of lumacaftor and ivacaftor (transmembrane conductance regulator stimulants)	FDA Breakthrough Therapy Designation 1/2013; NDA filed 11/2014
Asfotase	Enobia Pharma	INJ (SC)	Hypophosphatase	Recombinant fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphate (TNSALP)	FDA breakthrough therapy designation 5/2013; rolling BLA initiated 4/2014
Patiromer	Relypsa	PO	Hyperkalemia	Non-absorbed oral polymeric	NDA filed 10/2014

PRODUCT	MFR	ROUTE	INDICATION	PHARMACOLOGY	MARKET RELEASE
				compound known as patiomer, a potassium binder	
CEP-33237	Teva	PO	Moderate to severe pain	Hydrocodone extended release with abuse deterrent properties; dosed once daily	Phase III; Rolling NDA initiated 10/2014
MNK-155	Mallinkrodt	PO	Moderate to moderately severe acute pain	Hydrocodone and acetaminophen extended release	NDA submitted 5/2014